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 Bone substitutes are required for the healing of large bone defects, including 
orthopedic, craniofacial, and dental reconstructions.  Bone tissue engineering has 
emerged as a promising strategy to address the limitations of currently used bone 
substitutes.  The central paradigm of these approaches is the incorporation of cells, a 
scaffold, and bioactive factors into an implantable construct.  However, the efficacy of 
these strategies has been limited by the availability of a readily accessible, controlled, and 
sustained mineralizing cell source.  This work aims to meet this need by inducing 
osteoblastic differentiation of primary skeletal muscle cells by genetic engineering with 
the Runx2 osteoblastic transcription factor.  The overall objective of this research was to 
engineer an inducible cell source for bone tissue engineering that addresses the 
limitations of current cell-based approaches to orthopedic regeneration.  Our central 
hypothesis was that inducible Runx2 overexpression in skeletal myoblasts would 
stimulate differentiation into a regulated osteoblastic phenotype for bone tissue 
engineering applications. 
 We first tested the central hypothesis by retrovirally overexpressing a constitutive 
Runx2 transgene in primary skeletal muscle cells in monolayer culture.  Runx2 inhibited 
myogenic differentiation in these cells, as evident by downregulated muscle-specific gene 
expression and suppressed myotube formation.  Runx2 stimulated osteoblastic 
differentiation, as demonstrated by upregulation of osteoblastic gene expression and 
alkaline phosphatase biochemical activity.  Furthermore, Runx2-engineered myoblasts 
showed significant deposition of a hydroxyapatite mineral.  Interestingly, Runx2 
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overexpression had a more potent effect on osteoinduction relative to treatment with 
soluble BMP-2 protein, which may have been the result of bypassing BMP-2-stimulated 
autoregulatory factors.  Collectively, these results demonstrate that Runx2 stimulates 
transdifferentiation of primary skeletal muscle cells into an osteoblastic phenotype. 
 These cells were further examined in the environment of a three-dimensional 
tissue-engineered construct.  Runx2-engineered myoblasts or control cells were seeded 
onto fibrous collagen scaffolds and cultured up to 8 weeks in static conditions in vitro.  
Cells were viable on these scaffolds for prolonged culture times.  Runx2-engineered cells 
upregulated osteogenic and downregulated myogenic gene expression on the scaffolds, 
similar to cells in monolayer culture.  Finally, the Runx2-overexpressing myoblasts 
produced a hydroxyapatite mineral coating on these scaffolds.  Although mineral 
deposition was confined to the construct periphery, colocalizing with cell viability, the 
mineral coating was sufficient to improve the mechanical properties of the constructs 30-
fold.  These results established Runx2-engineered skeletal myoblasts as a promising cell 
source for bone tissue engineering. 
 Further characterization of these cells involved an in vitro and in vivo comparison 
with myoblasts retrovirally engineered to overexpress BMP-2, a well-characterized 
osteogenic factor used in bone tissue engineering strategies. Retroviral delivery of BMP-
2 or Runx2 stimulated differentiation into an osteoblastic phenotype, as demonstrated by 
the induction of osteogenic gene expression, alkaline phosphatase activity, and matrix 
mineralization in monolayer culture and on collagen scaffolds both in vitro and in an 
intramuscular site in vivo.  In general, BMP-2 stimulated osteoblastic markers faster and 
to a greater extent than Runx2, although experimental conditions were identified under 
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which these two factors produced similar effects.  Additionally, Runx2-engineered cells 
did not utilize paracrine signaling via secreted osteogenic factors, in contrast to cells 
overexpressing BMP-2, as demonstrated by conditioned media studies and activation of 
Smad signaling.  These results emphasize the complexity of gene therapy-based 
orthopedic therapeutics as an integrated relationship of differentiation state, proliferative 
capacity, construct maturation, and paracrine signaling of osteogenic cells.  This study 
was significant in evaluating proposed therapeutic systems and defining a successful 
strategy for integrating gene medicine and orthopedic regeneration.    
 Although ex vivo gene therapy is a promising approach to orthopedic regenerative 
medicine, the unregulated production of osteoinductive molecules has also resulted in 
abnormal bone formation and tumorigenesis.  To address these limitations, we developed 
a retroviral system to deliver the Runx2 osteoblastic transcription factor under control of 
the tetracycline-inducible (tet-off) promoter in primary skeletal myoblasts.  Runx2 
expression was tightly regulated by anhydrotetracyline (aTc) concentration in cell culture 
media.  Osteoblastic gene expression, alkaline phosphatase activity, and matrix 
mineralization were also controlled by aTc in a dose-dependent manner.  Additionally, 
osteoblastic differentiation was temporally regulated by adding and removing aTc from 
the culture media.  Engineered cells were seeded onto collagen scaffolds and implanted 
intramuscularly in the hind limbs of syngeneic mice.  In vivo mineralization by these 
constructs was regulated by supplementing the drinking water with aTc, as demonstrated 
by micro-computed tomography and histological analyses.  Collectively, these results 
present a novel system for regulating osteoblastic differentiation of a clinically relevant 
autologous cell source.  This system is significant in developing controlled and effective 
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orthopedic gene therapy strategies and studying the regulation of osteoblastic 
differentiation. 
 In summary, this work has established Runx2-engineered primary skeletal 
myoblasts as a promising cell source for bone tissue engineering.  These cells have been 
characterized in monolayer culture and in tissue engineered constructs in vitro and in 
vivo.  The degree of Runx2-stimulated osteoblastic differentiation compares favorably 
with that of BMP-2-based strategies, the current standard in orthopedic gene therapy.  
Finally, we have engineered a system to exogenously regulate Runx2-stimulated 
osteoblastic differentiation.  This work has successfully identified strategies to address 
cell sourcing limitations of bone tissue engineering and alternate methods for orthopedic 
gene therapy, as well as enhance our understanding of the molecular biology of 







 Bone tissue engineering has emerged as a promising alternative to currently used 
bone substitutes.  The central paradigm of these approaches is the incorporation of cells, a 
scaffold, and bioactive factors into an implantable construct.  However, the efficacy of 
these strategies has been limited by the availability of a sustained, mineralizing cell 
source.  In response to this need, ex vivo gene therapy with osteogenic factors has been 
used to enhance osteoblastic phenotype and in vivo bone healing.  The majority of these 
strategies utilize the constitutive overexpression of soluble signaling proteins, resulting in 
unregulated secretion of potent osteoinductive molecules which primarily act on native 
cells surrounding the implant site.  Although this method is successful in stimulating 
osteoblastic differentiation, this effect is unregulated with respect to magnitude and 
kinetics of cell activity. In contrast to these approaches, our group has previously 
demonstrated that genetic engineering of an osteogenic cell source with the osteoblastic 
transcription factor Runx2, an intracellular effector, dramatically enhances the phenotype 
and in vivo mineralization by these cells.  However, an autologous osteogenic cell source 
is painful and difficult to obtain in large numbers and has passage-dependent and age-
related decreases in mineralization.  This research focuses on using this strategy to induce 
osteogenesis in skeletal myoblasts, a source of mesenchymal progenitor cells available in 
large numbers and compatible with in vitro expansion and gene therapy protocols.  
Additionally, this project establishes methods to control the magnitude and kinetics of 
Runx2-induced osteogenesis as strategies to regulate the in vitro engineering of tissues 
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and circumvent the aberrant effects of unregulated overexpression of an osteogenic 
factor. 
 Our central hypothesis was that inducible Runx2 overexpression in skeletal 
myoblasts stimulates differentiation into a regulated osteoblastic phenotype for bone 
tissue engineering applications.  The overall objective of this research was to engineer an 
inducible cell source for bone tissue engineering that addresses the limitations of current 
cell-based approaches to orthopedic regeneration. 
 
Aim 1:  Analyze the effects of Runx2 overexpression in skeletal myoblasts. 
The effects of Runx2 expression in skeletal myoblasts were assessed in 
monolayer culture in vitro utilizing a constitutive retroviral delivery system.  The 
working hypothesis was that overexpression of the osteoblastic transcription factor Runx2 
stimulates differentiation of skeletal myoblasts into an osteoblastic phenotype.  
Osteoblastic differentiation was assessed by gene expression, alkaline phosphatase 
biochemical activity, and matrix mineralization.  Myogenic differentiation was assessed 
by gene expression and myotube formation.    
 
Aim 2:  Evaluate Runx2-overexpressing skeletal myoblasts as a mineralizing cell 
source for bone tissue engineering. 
 The working hypothesis was that Runx2-genetically engineered skeletal myoblasts 
produce a mineralized matrix in tissue-engineered constructs for bone tissue engineering 
applications.  Cell-seeded tissue-engineered constructs were cultured in vitro and 
analyzed for osteoblastic behavior and mineral deposition.  Engineered cells were also 
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implanted intra-muscularly in mice to assess the mineralization potential of these cells in 
vivo.  Mineralization was investigated by micro-CT, histological analysis, and FTIR 
spectroscopy.  Runx2-engineered cells were also compared to cells overexpressing BMP-
2, the standard soluble osteogenic factor used for gene therapy-based orthopedic 
regeneration. 
 
Aim 3:  Engineer a system to regulate the magnitude and kinetics of Runx2-
stimulated osteoblastic differentiation. 
 The working hypothesis was that the effects of Runx2 overexpression can be 
exogenously regulated by a retroviral tetracycline-inducible expression system.  Skeletal 
myoblasts were engineered with a tetracycline-inducible expression system incorporating 
the Runx2 gene.  Cells were then analyzed for osteoblastic differentiation in response to 
varying concentrations of tetracycline, including gene expression, alkaline phosphatase 
activity, and matrix mineralization.  Cells engineered with the inducible Runx2 
expression system were implanted intramuscularly into syngeneic mice receiving 
tetracycline though the drinking water.  Exogenous regulation of in vivo mineralization 
by these cells was monitored by micro-CT and histological analyses. 
 
 This work is significant because it provides insights into the biological role of the 
Runx2 transcription factor in determining cell lineage, addresses cell sourcing limitations 
of bone tissue engineering, and establishes a controlled and effective approach for 
orthopedic gene therapy.  This research is innovative because it utilizes overexpression of 
an osteoblastic transcription factor to redirect the differentiation of non-osteoblastic cells 
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for therapeutic applications and develops a unique strategy for the regulation of transgene 






Bone Structure and Function 
 Bone tissue serves several important functions in the human body1.  First, the 
skeleton provides structural support for the body and its associated tissues and organs.  
Bones such as the ribs, skull, and vertebrae also provide protection to vital organs 
including the heart, lungs, brain, and spinal cord.  The marrow cavities of bones serve as 
housing for bone marrow, cells of the immune system, and hematopoetic and 
mesenchymal stem cells.  Bone also acts as a reservoir and regulator of calcium and 
phosphate ions in the body, and provides attachment points for muscle, tendons, and 
ligaments to apply force and generate motion. 
 Bone consists of a cell-secreted protein matrix, predominantly consisting of type I 
collagen (>95%), as well as other noncollagenous calcium binding and signaling proteins, 
including osteocalcin, osteopontin, bone sialoprotein, and osteonectin2.  The mineral 
component of bone, representing 60-75% of the total weight, consists of hydroxyapatite, 
a poorly crystalline lattice structure of calcium and phosphate (Ca10(PO4)6(OH)2).  
Biological hydroxyapatite contains several ionic substitutions, most notably carbonate, 
and is embedded in an oriented fashion in the fibrillar collagenous matrix.  The human 
skeleton consists of trabecular and cortical bone.  Cortical bone constitutes the long 
bones, small bones, and flat bones, and is comprised of a hierarchy of geometric units to 
maximize the mechanical properties of the material.  Trabecular, or spongy, bone is 
present at the ends of long bones and is more porous and less stiff than cortical bone.  




 Bone consists of four major cell types, including osteoblasts, osteocytes, 
osteoclasts, and bone-lining cells2.  Osteoblasts are responsible for generating bone tissue 
at the bone surface, including matrix secretion and remodeling and mineral deposition3.  
Osteocytes are terminally differentiated osteoblasts which have become embedded within 
the bone matrix.  These cells are involved in sensing mechanical forces within the bone 
tissue and participate in the remodeling process.  Osteoclasts are large multi-nucleated 
cells of hematopoetic origin that resorb bone through mineral dissolution and enzymatic 
digestion of the organic matrix.  Bone-lining cells cover resting bone surfaces and can 
also regulate bone maintenance directly, or through the recruitment of osteoblasts or 
osteoclasts. 
 
Bone Formation and Healing 
 Bone formation, or ossification, occurs through two distinct mechanisms: 
intramembranous ossification and endochondral ossification2.  Endochondral ossification 
is responsible for the formation of bones of the extremities and weight bearing bones, 
such as vertebrae, and occurs via a preexisting cartilage template.  Hypertrophic 
chondrocytes at the bone-cartilage interface initiate calcification of the cartilage.  
Subsequently, these cells become apoptotic, leading to the invasion of vascular supply 
and osteoblasts that secrete the appropriate bone matrix.  This tissue subsequently fuses 
into an unstructured woven bone and is remodeled into lamellar bone of aligned collagen 
fibrils.  Intramembranous ossification occurs without a cartilage intermediate during the 
development of the flat bones of the skull and face.  Ossification begins with the 
infiltration of mesenchymal progenitor cells into a fibrous matrix and their subsequent 
osteoblastic differentiation.  These cells initiate the assembly of osteoid, the uncalcified 
bone matrix.  Trabecular bone and vascular structures then begin to form within this 
tissue.  As the trabecular bone fragments thicken they begin to fuse into continuous 
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plates, and the irregular woven bone is replaced via remodeling with structured lamellar 
bone.   
 Following bone damage, a hematoma and fibrin clot develop in the site of 
fracture.  Cells of the immune system, including macrophages and leukocytes, clean and 
remove the damaged tissue.  Osteoblasts and osteoprogenitors infiltrate the tissue from 
the blood stream and neighboring periosteal and marrow tissues and begin to secrete 
organic matrix which is subsequently mineralized1.  Importantly, this process may be 
hindered by infection, lack of blood supply, fracture instability, or lack of sufficient 
material.  In such cases, or when the fracture is too large to repair itself, bone grafting 
procedures may be necessary to repair the defect4. 
 
Osteoblastic Differentiation and the Runx2 Transcription Factor 
Osteoblastic differentiation has been described as a developmental sequence 
consisting of proliferation, matrix synthesis and maturation, and matrix mineralization5.  
Throughout the proliferative phase, osteoblast activity is primarily restricted to type I 
collagen secretion.  As proliferation decreases, differentiation is marked by a transient 
increase in alkaline phosphatase activity.   The mature osteoblastic phenotype is 
characterized by osteocalcin expression, which is upregulated before the initiation of 
matrix mineralization.  Terminal osteoblastic differentiation is associated with 
hydroxyapatite deposition in the secreted organic matrix.     
Osteoblastic differentiation has primarily been studied through experiments with 
soluble osteoinductive factors discovered in demineralized bone matrix, most notably 
bone morphogenetic proteins (BMPs)6.  Osteogenic induction by BMPs has been 
extensively studied in myogenic and pluripotent cell lines and primary cells.  BMPs, a 
subdivision of the transforming growth factor beta (TGF-β) superfamily, comprise a 
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highly conserved and expanding family of 15 genes critical to embryogenesis and bone 
formation7,8.  The exceedingly complex molecular mechanisms of BMP signaling are 
under continuous investigation, but several important aspects of select pathways have 
been determined.  BMP-2 acts as a dimer by binding to a heterotetramer of type I and 
type II transmembrane serine/threonine kinase receptor proteins, inducing 
autophosphorylation of the intracellular domains.  Upon activation by BMP-2, these 
receptors phosphorylate the intracellular signaling molecule Smad1/5.  Activated 
Smad1/5 then associates with Smad4 and translocates to the nucleus, where it interacts 
with the osteoblast-specific transcription factor Runx2/Cbfa1/Osf2/AML3 and 
upregulates osteoblastic gene expression9,10.  BMP-2 induces osteoblastic markers in the 
myogenic C2C12 and pluripotent C3H10T1/2 cell lines, including increased alkaline 
phosphatase activity and osteocalcin mRNA expression and promoter activity11-14.  BMP-
2 also suppresses myogenesis in these cell lines, which is typically demonstrated by 
inhibited myotube formation and reduced activity of myogenic regulatory factors 
(MRFs), such as MyoD and myogenin15,16.  MyoD determines myoblastic cell fate, and 
myogenin acts downstream of MyoD by regulating commitment to myogenic 
differentiation17.  Upregulation of Id-1 (inhibitor of differentiation/DNA binding-1) by 
BMP-2 is responsible for reduction of MRF activity by competitively binding E proteins 
that are necessary for MRF function18,19.     
Runx2, a member of the runt homology domain family of transcription factors, is 
required for osteoblastic differentiation and endochondral and intramembranous bone 
formation20,21.  Heterozygous mutation of the Runx2 gene is implicated in the human 
skeletal disorder cleidocranial dysplasia22,23, and the homozygous mutation in mice 
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results in a complete lack of mineralization and immediate postnatal death21.  Our 
laboratory has previously demonstrated that sustained expression of Runx2 in osteogenic 
and pluripotent cell lines upregulates osteoblast-specific gene expression and induces in 
vitro mineralization in a cell type-dependent manner24.  These results established the 
requirement for other cofactors in addition to Runx2 to induce cell-mediated 
mineralization.  These results also demonstrate that increased osteocalcin expression and 
alkaline phosphatase activity are insufficient markers to define terminal and functional 
osteoblastic differentiation (e.g. matrix mineralization).   
 BMP-2-induced osteogenesis has several known points of regulation upstream of 
Runx2 transcriptional activation.  The protein noggin blocks the extracellular interaction 
of BMPs with their receptors by competitive dimerization25,26.  The inhibitory smad, 
Smad6, blocks BMP signaling by physically preventing the interaction between BMP 
receptors and Smad1/5, and inhibiting subsequent activation7.  Smad5 signaling can also 
be blocked by Smurf1, which targets Smad5 for degradation and thereby facilitates 
myogenic differentiation and antagonizes BMP-2 induced osteogenesis27,28.  Finally, 
Runx2 activity can be directly regulated by other transcription factors such as HES-1, 
Msx2, Dlx5, and TLE proteins.  The basic helix loop helix protein HES-1 promotes 
Runx2 transcriptional activity in ROS17/2.8 cells through a direct physical interaction29.  
The homeobox protein Msx2 is expressed in proliferating immature osteoblasts and 
inhibits terminal osteoblastic differentiation, possibly by repressing Runx2 activity30,31.  
Dlx5, another homeobox protein which is expressed in differentiating osteoblasts, is 
required for BMP-2 induced osteogenesis and modulates Runx2 activity by inhibiting 
Msx2-mediated suppression31-33.  TLE1 and TLE2 colocalize with Runx2 in the nucleus 
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and repress its activity via interactions with the Runx2 C-terminal transactivation 
domain34.  The numerous levels of regulation in this cascade indicate that signaling via 
BMP-2 stimulation does not necessarily result in robust and exclusive Runx2 
transcriptional activity and other accessory signaling pathways modulate signal 
transduction.   
 
Bone Grafting 
Orthopaedic reconstructions have a significant socioeconomic impact worldwide, 
as evidenced by the 2.2 million operations requiring bone substitutes each year4.  Existing 
bone substitutes include autografts, allografts, and synthetic materials35,36.  Autografting 
involves the harvest of autogenous bone, typically from the iliac crest, for implantation 
into an osseous defect.  Although successful in many cases, this procedure is limited by 
the availability of healthy tissue, donor site morbidity, and pain associated with the 
harvest4,36.  Allografts, typically cadaver bone from bone banks, suffer from reduced 
biological and mechanical properties after processing and possible disease transmission4.  
Synthetic materials, including titanium, ceramics, and synthetic hydroxyapatite, generally 
incite host inflammation and fail to adequately integrate and remodel with the 
surrounding native tissue37.  Bone tissue engineering has emerged as a promising 
alternative to these strategies.  The general paradigm of these approaches focuses on 
incorporating cells, a scaffold, and bioactive factors into an implantable construct38,39.  
 
Cell Sources for Bone Tissue Engineering 
 Current applications of bone tissue engineering have been hindered by availability 
of a sustained, mineralizing cell source that can generate mechanically robust constructs 
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for large defects.  Terminally differentiated osteoblasts, the cells responsible for bone 
formation, are difficult to obtain in large numbers and fail to proliferate and substantially 
populate typical tissue-engineered constructs.  Immortalized osteogenic cell lines have 
the potential to form tumors in vivo.  Osteogenic precursors, such as bone marrow 
stromal cells, are capable of osteoblastic differentiation and mineralization40, and have 
been used in many cases to successfully heal bone defects41-46.  However, these cells are 
also difficult and painful to obtain in suitable quantities38, typically de-differentiate and 
lose phenotype following in vitro culture and expansion47-49, and demonstrate an age-
related decrease in osteogenic capacity50.  A promising alternative to these cell sources is 
the induction of sustained osteogenesis in non-osteoblastic cells using genetic 
engineering approaches.   
BMPs have been used extensively to induce osteogenesis in non-osteoblastic cell 
types, including bone marrow stromal cells51-54, dermal and gingival fibroblasts55,56, and 
skeletal myoblasts13,57.  In fact, skeletal myoblasts have been used extensively in 
combination with BMPs to generate bone tissue in both ectopic and osseous 
environments58-60.  Skeletal myoblasts represent a clinically relevant autologous source of 
mesenchymal progenitor cells that are readily accessible in large quantities from muscle 
biopsies.  They are easily purified and expanded under the appropriate culture conditions 
and contain a subpopulation of muscle-derived stem cells61.  Furthermore, the use of 
autologous cells in a clinical setting avoids immunological complications involved in 
allogeneic and xenogeneic cell-based strategies.  Myoblasts are also compatible with 







Orthopedic Gene Therapy 
Gene Delivery Systems 
 Orthopedic gene therapy consists of in vivo approaches, when the gene delivery 
vehicle is directly implanted or injected into the body, and ex vivo strategies, when cells 
are genetically manipulated in vitro and subsequently implanted into the bone defect63.  
Both approaches have been widely used for bone regeneration.  Although in vivo gene 
therapy benefits from the simplicity of a cell-free approach, ex vivo gene therapy allows 
for greater efficiency and target specificity and avoids the safety risks involved with 
direct exposure to gene carriers. 
 Gene delivery vehicles for orthopedic regeneration have included plasmid DNA64 
and viral gene carriers, including retrovirus43,65-67, lentivirus68, adenovirus69,70, and adeno-
associated virus71-73.  Although plasmid DNA is easy to produce, has low 
immunogenicity, and avoids many safety issues associated with viral gene delivery, this 
method is still hindered by limitations of toxicity, specificity, and efficiency.  However, 
systems incorporating plasmid DNA into complexes with cationic lipids or polymers are 
currently under development to address these concerns74.   
 Viruses have been selected through evolution for the ability to enter cells and 
deliver their genetic material into the nucleus of target cells and are therefore much more 
efficient than methods involving plasmid DNA.  Adenoviruses contain a DNA genome 
and enter the cell by binding to virus receptors and inducing internalization through 
interactions with integrins.  Once inside the cell, the virion disassembles and the DNA is 
released into the nucleus, where it remains as an episome for days/weeks before 
degradation.  Adenoviruses display high transduction efficiencies of most cell types, have 
a large cloning capacity (36 kb), and can be prepared at high titers.  However, the 
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significant inflammatory response incited by adenoviral capsid proteins and pre-existing 
antibodies to these particles limit their efficacy in vivo.  Adeno-associated viruses have 
recently emerged as a particularly promising delivery vehicle considering the broad cell 
tropism and lack of an inflammatory response.  These vectors generally remain as a 
transient episome within the nucleus, although a fraction of particles do integrate into the 
chromosomal DNA.  The major limitation of this vector is the small cloning capacity (<5 
kb), thus prohibiting the delivery of large or multiple genes with a single vector.  
Retroviral and lentiviral vectors contain an RNA genome with moderate cloning capacity 
(8 kb) that can integrate into chromosomal DNA, thus making these vectors attractive for 
gene therapy strategies that require prolonged expression.  However, retroviral transgene 
expression may still be limited by gene methylation or promoter silencing.  Integration 
into chromosomal DNA can also cause insertional mutagenesis, in which pathological 
states are caused by deregulation of endogenous gene expression by the integrated vector.  
While retroviruses can only transduce dividing cells, since they require breakdown of the 
nuclear membrane to gain access to host DNA, lentiviruses can transduce both dividing 
and nondividing cells.  The optimal gene delivery vehicle for a specific application is 
typically selected based on the desired expression kinetics, cloning capacity, 
biocompatibility, and susceptibility of the target cell type. 
 
Osteogenic Transgenes 
 The vast majority of orthopedic gene therapy strategies focus on the 
overexpression of BMPs.  In particular, BMP-252,68,75, BMP-464,66, and BMP-743,55 have 
all been used to stimulate osteoblastic differentiation and bone formation.  BMP-
engineered cells are particularly potent inducers of bone formation in vivo, as secreted 
BMP protein can stimulate the differentiation of native osteoprogenitors76.  The 
considerable success of BMP-based strategies led to the targeting of downstream 
regulators of BMP signaling, particularly the Runx2 transcription factor.  Runx2-based 
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gene therapy has been successful in stimulating osteoblastic differentiation of bone 
marrow stromal cells and enhancing bone formation and repair.56,67,77-79  Additionally, 
coexpression of osteogenic and angiogenic factors, such as VEGF, has led to a 
synergistic enhancement in bone healing64,72,80.  Promising results have also been 
achieved with strategies focusing on RANK-L,72 constitutively active BMP receptors,73 
LIM-mineralization protein,81 and synergistic approaches incorporating multiple 
transgenes70,78 and transgenes supplemented with glucocorticoids82,83 or 
immunosuppressive agents.84,85   
 
Inducible Expression Systems 
Constitutive overexpression of osteogenic transgenes has been successful in 
stimulating osteoblastic differentiation and bone regeneration.  However, the unregulated 
overexpression of these proteins also risks aberrant effects of uncontrolled cell signaling, 
including tumorigenesis86,87 and bone overproduction,88,89 when bone growth exceeds the 
defect site.  Inducible expression systems have been utilized to address these concerns 
and control the activity of genetically engineered cells.74  These systems typically drive 
transgene expression from inducible promoters regulated by engineered and/or non-
mammalian transcription factors.  The activity of these transcription factors is controlled 
by exogenous chemical agents which permit (“on” state) or repress (“off” state) transgene 
expression.  In principle, an ex vivo inducible gene therapy strategy involves implanting 
engineered cells into a bone defect site and maintaining an optimized level of transgene 
expression in the “on” condition.  When adequate healing has occurred, cells are moved 
to the “off” condition to prevent any adverse effects of prolonged transgene 
overexpression.  Additionally, incorporating regulation into these systems allows analysis 
of unique patterns of transgene expression, including varying the duration and magnitude 
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of expression, cycling expression over time, and coordinating the sequential presence of 
multiple exogenously expressed genes.   
The most widely characterized of these systems is the tetracycline inducible 
expression system, first described by Gossen and Bujard.90  The original system utilizes 
the tetracycline-controlled transactivator (tTA).  In the absence of tetracycline, tTA binds 
the tet operon and activates transcription of a downstream gene of interest.  However, in 
the presence of subtoxic levels of tetracycline, the antibiotic binds to tTA, blocking 
binding of the tet operon and subsequent transactivation in a dose-dependent manner.  
This system is compatible in vitro by adding tetracycline to the cell culture media and in 
vivo by delivering aTc via the drinking water.   This “tet-off” version was later modified 
to a “tet-on” system, in which transactivation increases with tetracycline concentration.91  
Despite the greater clinical relevance of the tet-on derivative, the tet-off system is widely 
reported as having a greater degree of inducibility, including lower expression levels in 
the “off” state and higher expression levels in the “on” state.92  However, recent 
modifications of the “tet-on” system have shown improved induction levels and lower 
basal activity in the “off” state.93,94  Many other promising inducible expression systems 
have been designed based on promoters that are responsive to a variety of environmental 
and physiological stimuli.74,95  The clinical success of these systems will be dependent on 
the efficient delivery of multiple vectors, biocompatibility of the inducing agent, 
immunologic tolerance of the engineered or non-mammalian protein components, limited 
promoter interference, efficient repression in the “off” state, and appropriate expression 
levels in the “on” state. 
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Inducible expression systems have been incorporated into genetic engineering 
strategies for regulated osteoblastic differentiation and bone regeneration.  Gazit and 
colleagues initially utilized the “tet-off” system to regulate in vitro osteoblastic 
differentiation, ectopic bone formation, and regeneration of a long bone segmental defect 
by a BMP-2-engineered mesenchymal stem cell line.88  This system was subsequently 
used to direct spinal fusion96 and study the kinetics of BMP-2-induced osteochondral 
differentiation.97  Building on these promising results, the BMP-2 transgene was 
incorporated into an AAV-2-based “tet-on” expression system for in vivo gene delivery 
by direct viral injection.71  This approach was successful in effectively controlling ectopic 
bone formation and repairing critically-sized cranial defects.  Peng et al. have also 
exploited a retroviral tetracycline-regulated gene expression system to control bone 
formation by BMP-4-engineered muscle-derived stem cells.65  Additionally, this study 
identified optimal self-inactivating deletions within the retroviral long terminal repeat to 
enhance expression from the inducible promoter, which may be limited in certain 
applications due to promoter interference.98  This system was also used in combination 
with overexpression of autoregulatory factors, providing an additional level of control 





RUNX2-STIMULATED TRANSDIFFERENTIATION OF  
PRIMARY SKELETAL MYOBLASTS INTO AN  
OSTEOBLASTIC PHENOTYPE*  
Introduction 
 Osteogenic induction by bone morphogenetic proteins (BMPs) has been 
extensively studied in myogenic and pluripotent cell lines and primary cells.  BMPs, a 
subdivision of the transforming growth factor beta (TGF-β) superfamily, comprise a 
highly conserved and expanding family of 15 genes critical to embryogenesis and bone 
formation7,8.  The exceedingly complex molecular mechanisms of BMP signaling are 
under continuous investigation, but several important aspects of select pathways have 
been determined.  BMP-2 acts as a dimer by binding to a heterotetramer of type I and 
type II transmembrane serine/threonine kinase receptor proteins, inducing 
autophosphorylation of the intracellular domains.  Upon activation by BMP-2, these 
receptors phosphorylate the intracellular signaling molecule Smad1/5.  Activated 
Smad1/5 then associates with Smad4 and translocates to the nucleus, where it interacts 
with the osteoblast-specific transcription factor Runx2/Cbfa1/Osf2/AML3 and 
upregulates osteoblastic gene expression9,10.  BMP-2 induces osteoblastic markers in the 
myogenic C2C12 and pluripotent C3H10T1/2 cell lines, including increased alkaline 
phosphatase activity and osteocalcin mRNA expression and promoter activity11-14.  BMP-
2 also suppresses myogenesis in these cell lines, which is typically demonstrated by 
* Modified from 
C.A. Gersbach, B.A. Byers, G.K. Pavlath, and A.J. Garcia, Runx2/Cbfa1 stimulates transdifferentiation of 




inhibited myotube formation and reduced activity of myogenic regulatory factors 
(MRFs), such as MyoD and myogenin15,16.  MyoD determines myoblastic cell fate, and 
myogenin acts downstream of MyoD by regulating commitment to myogenic 
differentiation17.  Upregulation of Id-1 (inhibitor of differentiation/DNA binding-1) by 
BMP-2 is responsible for reduction of MRF activity by competitively binding E proteins 
that are necessary for MRF function18,19.     
Runx2, a member of the runt homology domain family of transcription factors, is 
required for osteoblastic differentiation and endochondral and intramembranous bone 
formation20,21.  Heterozygous mutation of the Runx2 gene is implicated in the human 
skeletal disorder cleidocranial dysplasia22,23, and the homozygous mutation in mice 
results in a complete lack of mineralization and immediate postnatal death21.  We have 
previously demonstrated that sustained expression of Runx2 in osteogenic and pluripotent 
cell lines upregulates osteoblast-specific gene expression and induces in vitro 
mineralization in a cell type-dependent manner24.  These results established the 
requirement for other cofactors in addition to Runx2 to induce cell-mediated 
mineralization.  These results also demonstrate that increased osteocalcin expression and 
alkaline phosphatase activity are insufficient markers to define terminal and functional 
osteoblastic differentiation (e.g. matrix mineralization).   
 BMP-2-induced osteogenesis has several known points of regulation upstream of 
Runx2 transcriptional activation.  The protein noggin blocks the extracellular interaction 
of BMPs with their receptors by competitive dimerization25,26.  The inhibitory smad, 
Smad6, blocks BMP signaling by physically preventing the interaction between BMP 
receptors and Smad1/5, and inhibiting subsequent activation7.  Smad5 signaling can also 
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be blocked by Smurf1, which targets Smad5 for degradation and thereby facilitates 
myogenic differentiation and antagonizes BMP-2 induced osteogenesis27,28.  Finally, 
Runx2 activity can be directly regulated by other transcription factors such as HES-1, 
Msx2, Dlx5, and TLE proteins.  The basic helix loop helix protein HES-1 promotes 
Runx2 transcriptional activity in ROS17/2.8 cells through a direct physical interaction29.  
The homeobox protein Msx2 is expressed in proliferating immature osteoblasts and 
inhibits terminal osteoblastic differentiation, possibly by repressing Runx2 activity30,31.  
Dlx5, another homeobox protein which is expressed in differentiating osteoblasts, is 
required for BMP-2 induced osteogenesis and modulates Runx2 activity by inhibiting 
Msx2-mediated suppression31-33.  TLE1 and TLE2 colocalize with Runx2 in the nucleus 
and repress its activity via interactions with the Runx2 C-terminal transactivation 
domain34.  The numerous levels of regulation in this cascade indicate that signaling via 
BMP-2 stimulation does not necessarily result in robust and exclusive Runx2 
transcriptional activity and other accessory signaling pathways modulate signal 
transduction.  Therefore, it is difficult to derive conclusions about the 
specific function of Runx2 using BMP-2 induction, whereas direct exogenous 
expression provides a more accurate depiction of the activity of Runx2 in the 
absence of extraneous BMP-2 signals.  
While numerous studies have assessed the effects of BMPs on myogenic cells, 
this work evaluates the effect of the downstream transcription factor Runx2 on the 
differentiation of primary skeletal myoblasts.  Transient upregulation of Runx2 in 
response to TGF-β is not sufficient for osteoblastic differentiation, and it has been 
suggested that sustained Runx2 expression may be necessary for commitment to the 
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osteoblastic phenotype14,99.  Additionally, several groups have observed minimal 
mineralization capacity of cells transiently expressing Runx2 by adenoviral delivery56,78.  
Therefore, we used retroviral delivery of Runx2 to assess the effects of sustained and 
significant exogenous expression levels.  We have included samples treated with BMP-2 
at 300 ng/ml as a reference to the extensive literature involving BMP-2 and myogenic 
cells.  Interestingly, not only did forced expression of this single transcription factor 
redirect the fate of these cells, but the effect was greater than that of treatment with the 
BMP-2 growth factor.  These results demonstrate that sustained Runx2 expression 
induces transdifferentiation of primary skeletal myoblasts into an osteoblastic phenotype, 
including osteogenic gene expression, enzyme activity, and biological mineral deposition.  
 
Materials and Methods 
Cell Culture 
 Primary myoblasts were isolated from the tibialis anterior muscles of adult male 
Balb/c mice and cultured in selective growth media (Ham’s F10, 20% fetal bovine serum, 
5 ng/ml bFGF (Promega, Madison, WI), 100 U/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate), yielding cultures that were greater than 99% myogenic by desmin 
staining100.  Cells were cultured on tissue culture plastic dishes coated with 0.01% type I 
collagen (Vitrogen, Palo Alto, CA) in a humidified 5% CO2 atmosphere at 37 ºC.  Cell 
culture media and antibiotics were obtained from Invitrogen (Carlsbad, CA), fetal bovine 
serum was purchased from Hyclone (Logan, UT), and all other cell culture supplements 





The Runx2 retroviral vector24 uses the promoter activity of the 5’ long terminal 
repeat (LTR) to express a single bicistronic mRNA encoding the murine cDNA for the 
type II MASNSLF Runx2 isoform101,102, followed by an internal ribosomal entry site 
(IRES) and a zeocin resistance-enhanced green fluorescent protein fusion protein 
(Zeo:eGFP), allowing for noninvasive analysis of transduction efficiency (Fig. 3.1A).  
Plasmid DNA was purified from transformed E. coli using Megaprep kits from Qiagen 
(Valencia, CA).  Retroviral stocks were produced by transient transfection of helper-virus 
free ΦNX amphotropic producer cells with plasmid DNA as previously described24.  
ΦNX cells were cultured in growth media (DMEM, 10% fetal bovine serum, 100 U/ml 
penicillin G sodium, 100 µg/ml streptomycin sulfate) in a humidified 5% CO2 
atmosphere at 37 °C and plated 9 x 104 cells/cm2 24 h prior to transfection.  Cells were 
transfected with 0.5 µg/cm2 of plasmid DNA, either Runx2 or empty vector (no Runx2 
insert), using calcium phosphate coprecipitation and 25 µM chloroquine for 8-12 h prior 
to refeeding with fresh growth media.  Twenty-four hours after the start of the 
transfection, media was replaced with fresh growth media and dishes were transferred to 
a humidified 5% CO2 atmosphere at 32 °C for enhanced stability of retroviral particles.  
Retroviral supernatants were collected at 48, 60, and 72 h post-transfection, filtered 
through a 0.45 µm cellulose acetate filter, aliquoted, snap frozen, and stored at -80 °C 
until use. 
  Primary myoblasts were cultured up to 12 passages and plated on 0.01% collagen-
coated tissue culture polystyrene at 2 x 104 cells/cm2 24 h prior to retroviral 
transduction62.  Cells were transduced with 0.2 ml/cm2 of retroviral supernatant 
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supplemented with 4 µg/ml hexadimethrine bromide (Polybrene), 5 ng/ml bFGF, and 
10% fetal bovine serum, and centrifuged at 2500 rpm (1200 g) for 30 min in a Beckman 
model GS-6R centrifuge with a swinging bucket rotor.  After infection, growth media 
was reapplied, and the cells were returned to 37°C and transduced again 12-16 h later to 
increase transduction efficiency.  After the final transduction, retroviral supernatants were 
replaced with differentiation media (αMEM, 10% fetal bovine serum, 100 U/ml penicillin 
G sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid and 2.1 mM sodium 
β-glycerophosphate), supplemented with or without 300 ng/ml recombinant BMP-2 
(Kamiya Biomedical, Seattle, WA).  Cell culture media and BMP-2 were replaced every 
3 days until terminal assay.  No differences were observed between empty vector 
retrovirus (negative control) and unmodified cells in all experiments.   
 
Real Time RT-PCR 
Total RNA was isolated at 1, 3, and 7 days post transduction using the RNeasy 
RNA isolation kit (Qiagen).  cDNA synthesis was performed on DNaseI-treated (27 
Kunitz units/sample) total RNA (1 µg) by oligo(dT) priming using the Superscript™ First 
Strand Synthesis System for RT-PCR (Invitrogen).  Real-time PCR using SYBR Green 
intercalating dye was performed with the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA, 40 cycles, melting: 15 sec at 95ºC, annealing and 
extension: 60 sec at 60ºC)24.  Real-time PCR oligonucleotide primers (Table 3.1) were 
designed using ABI Primer Express software and purchased from IDTDNA (Coralville, 
IA).  Primer specificity was confirmed by agarose gel electrophoresis and ABI Prism 
7700 Dissociation Curve Software.  Standards for each gene were amplified from cDNA 
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using real-time oligonucleotides (Table 3.1), purified using a Qiagen PCR Purification 
kit, and diluted over a functional range of concentrations.  Transcript concentration in 
template cDNA solutions was quantified from a linear standard curve, normalized to 1 µg 
of total RNA, and expressed as femtomoles of transcripts per µg of total RNA.  Detection 
limits for each gene were determined by reactions without cDNA and were at least an 
order of magnitude below the most dilute sample. 
 
Western Blotting 
 Cells were washed with PBS and lysed in cold radioimmunoprecipitation assay 
(RIPA) buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 
150 mM Tris-HCl pH 7.2, 350 µg/ml phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 
10 µg/ml aprotinin, and 1 mM sodium orthovanadate) for 20 min.  Lysates were pipetted 
up and down ~25 times to shear the DNA and then clarified by centrifugation at 10,000g 
for 10 min.  Protein concentration was then determined using a Micro BCA protein assay 
kit (Pierce, Rockford, IL).  Equal amounts of protein (25 µg) were boiled in Laemmli 
sample buffer (2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris-HCl pH 6.8, and 
0.001% bromophenol blue) for 10 min and separated by SDS-PAGE.  Proteins were 
transferred by electrophoresis onto nitrocellulose membranes and blocked with Blotto 
(5% non-fat dry milk, 0.02% sodium azide, 0.2% Tween 20 in PBS w/o Ca2+/Mg2+) 
overnight at 4ºC.  Membranes were then incubated with 1 µg/ml anti-AML3 (Oncogene, 
San Diego, CA) or 9 µg/ml anti-GAPDH (Chemicon, Temecula, CA) in Blotto for 1 h at 
room temperature under gentle rocking.  Membranes were washed in TBS-Tween (20 




Table 3.1. Oligonucleotides for Real Time PCR
Target cDNA (Accession #) Sense Primer Antisense Primer
Runx2 (AF010284) 5’-AGCCTCTTCAGCGCAGTGAC-3’ 5’-CTGGTGCTCGGATCCCAA-3’
MyoD (XM_124916) 5’-CGGCTACCCAAGGTGGAGAT-3’ 5’-ACCTTCGATGTAGCGGATGG-3’
Myogenin (NM_031189) 5’-CTGACCCTACAGACGCCCAC-3’ 5’-TGTCCACGATGGACGTAAGG-3’
Id-1 (XM_130599) 5’-ACGACATGAACGGCTGCTACT-3’ 5’-GCTCACTTTGCGGTTCTGG-3’
Osteocalcin (X04142) 5’-CGGCCCTGAGTCTGACAAA-3’ 5’-GCCGGAGTCTGTTCACTACCTT-3’
Alkaline Phosphatase (NM_007431) 5’-GGGACTGGTACTCGGATAACGA-3’ 5’-CTGATATGCGATGTCCTTGCA-3’
Bone Sialoprotein (L20232) 5’-TCCTCCTCTGAAACGGTTTCC-3’ 5’-GGAACTATCGCCGTCTCCATT-3’
Osterix (AF184902) 5’-CCCCTGCTCCTTCTAGGCC-3’ 5’-CCGTCAACGACGTTATGCTCT-3’
Dlx5 (NM_010056) 5’-TCAGTACCTCGCCCTGCC-3’ 5’-TGTGTTTGCGTCAGTCCTAGAGA-3’
Noggin (NM_008711) 5’-AGCGAGATCAAAGGGCTGG-3’ 5’-CTCAGGCGCTGTTTCTTGC-3’
Smad6 (AF010133) 5’-AAGATCGGTTTTGGCATACTGC-3’ 5’-CCCCGGTTGTAGGCCC-3’
Msx2 (NM_013601) 5’-CCGCCGCCCAGACATAT-3’ 5’-TTCCGGTTGGTCTTGTGTTTC-3’
HES-1 (NM_008235) 5’-GGAGAGGCTGCCAAGGTTTT-3’ 5’-GCAAATTGGCCGTCAGGA-3’  
secondary antibody (biotin-conjugated anti-rabbit/mouse IgG, 1:20,000 dilution in Blotto, 
Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature.  Membranes 
were washed again in TBS-Tween for 30 min and incubated in tertiary antibody (alkaline 
phosphatase-conjugated anti-biotin IgG, 1:10,000 dilution in Blotto, Sigma) for 1 h at 
room temperature.  After antibody incubation, membranes were washed in TBS-Tween 
for 30 min and immunoreactivity was detected using ECF fluorescent substrate 
(Amersham Bioscience, Piscataway, NJ) and a Fuji Image Analyzer.   
 
Immunofluorescence Staining 
 At 7 days post-transduction, cells were fixed in 70% ethanol:37% 
formaldehyde:glacial acetic acid (20:2:1) for 10 min and blocked in 5% horse serum for 1 
h.  Cells were stained for myosin and DNA with mouse anti-sarcomeric myosin antibody 
MF20 (3.2 µg/ml, Developmental Studies Hybridoma Bank, Iowa City, IA) for 1 h, 
followed by biotin-SP-conjugated donkey anti-mouse IgG (3.75 µg/ml, Jackson 
ImmunoResearch) for 1 h, followed by anti-biotin FITC conjugate (10 µg/ml, Sigma) and 
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ethidium homodimer-2 (200 nM, Molecular Probes, Eugene, OR) for 1 h.  Cells were 
washed twice with PBS and incubated for 10 min in 5% horse serum after each antibody 
incubation.  Images of stained cells were captured using a Nikon Eclipse E400 
fluorescence microscope with a 20X objective, SPOT RT camera, and ImagePro Plus 
image acquisition software (Media Cybernetics, Silver Springs, MD).   
 
Alkaline Phosphatase Biochemical Activity 
 
As a marker of osteoblastic enzyme activity, alkaline phosphatase (ALP) activity 
was quantified at 7 days post-transduction as previously described24.  Cells were rinsed 
and scraped into ice-cold 50 mM Tris⋅HCl, pH 7.4.  Following sonication and 
centrifugation, total soluble protein concentration was quantified using the MicroBCA 
Protein Assay Kit.  Equal amounts of protein (2.5 µg) were added to 60 µg/mL 4-methyl-
umbelliferyl-phosphate fluorescent substrate in diethanolamine buffer (pH 9.5).  
Following incubation for 60 min at room temperature, the fluorescence was read at 360 
nm excitation/465 nm emission on an HTS 7000 Plus BioAssay Reader (Perkin Elmer, 
Norwalk, CT).  Enzymatic activity was standardized using purified calf intestinal alkaline 
phosphatase (Sigma) and normalized to total protein concentration. 
 
von Kossa Histochemical Analysis 
Cultures were fixed in 70% ethanol at 14 and 21 days and examined 
histochemically for mineralized matrix by von Kossa staining for phosphate deposits.  
Plates were stained with 5% AgNO3 under uniform light exposure for 30 min, fixed in 
5% Na2SO3 for 2 min, and air-dried.  Mineralized surface area was quantified by 
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automated capturing and averaging of twenty-four representative 2X images using Image 
Pro analysis software. 
 
FTIR Spectroscopy 
 Cell culture samples at 21 days post-transduction were fixed in 100% ethanol, 
scraped from the culture dish, and dried at 50ºC overnight.  Bone samples were scraped 
from a lyophilized rat cranium.  Bulk samples were mixed with KBr (Sigma) and pressed 
into pellets.  Samples were analyzed with a Nicolet Nexus 470 FTIR spectrometer 
(ThermoNicolet, Madison, WI) equipped with a DTGS detector.  64 scans were acquired 
at 4 cm-1 resolution under N2 purge.  
 
Data Analysis 
All analyses were performed on assays conducted at least three times, each with 
unique Runx2 retroviral supernatant preparations, and two independent isolates of 
primary skeletal myoblasts.  No differences were observed between unmodified and 
empty vector transduced cells in all assays.  Data are reported as mean ± standard error of 
the mean (SEM), and statistical comparisons using SYSTAT 8.0 were based on an 
analysis of variance (ANOVA) and Tukey’s test for pairwise comparisons within 
timepoints, with a p-value < 0.05 considered significant.  In order to make the variance 
independent of the mean, statistical analysis of real-time PCR data was performed 






Retrovirally transduced cells were analyzed for eGFP expression by fluorescence 
microscopy and flow cytometry, using a Becton-Dickinson FACS Vantage SE Cell Sorter 
(Fig. 3.1A).  High levels of eGFP were detected in approximately 50% of the cells at 72 h 
post-transduction.  Transgene expression was still detectable at 21 days post-transduction 
(data not shown), demonstrating sustained and integrated expression of the target gene by 
the retroviral vector.  Runx2 mRNA expression was assessed by real time RT-PCR in 
transduced cells and samples treated with 300 ng/ml of BMP-2 as a reference to the 
extensive literature involving BMP-2 and myogenic cells (Fig. 3.1B).  Runx2 mRNA 
expression was upregulated by BMP-2 at 3 and 7 days relative to control cells,  and was 
elevated approximately three orders of magnitude over both BMP-2-treated and control 
cells in Runx2-transduced cells at all time points.  Substantial amounts of Runx2 protein 
were detected by Western blotting at approximately 60 kDa in transduced samples at 3 
and 7 days post-transduction (Fig. 3.1C).  Runx2 protein was not detectable in BMP-2 
treated cells, likely due to lower levels of the transcription factor present in these 
samples.  
 
Forced Expression of Runx2 Inhibits Myogenesis 
 Myogenesis is a complex process, regulated by MRFs, in which mononucleated 
myoblasts terminally differentiate and fuse into large multinucleated myotubes capable of 
contraction.  Myogenesis was induced in skeletal myoblasts by culture in differentiation 
media, and gene expression was assessed at 1, 3, and 7 days post-retroviral transduction 











































Day 1 Day 3 Day 7



















































Figure 3.1.  Retroviral expression of Runx2 in primary skeletal myoblasts.  (A)  
Detection of transduction efficiency by eGFP expression by flow cytometry at 3 days 
post-transduction.  Unmodified cells were used to detect autofluorescence.  Empty vector 
and Runx2 vector transduced approximately 50% of primary myoblasts.  (B)  Runx2 
mRNA expression determined by real time RT-PCR at 1, 3, and 7 days post-transduction 
(Mean + SEM, n=6).  Runx2 expression was upregulated by BMP-2 at 3 and 7 days and 
by approximately three orders of magnitude in transduced cultures.  * different from 
Empty Vector, † different from BMP-2, (p<7E-6).  (C)  Runx2 protein levels analyzed by 
Western blotting at 3 and 7 days.  Significant amounts of Runx2 (~60 kDa) were present 
in transduced cultures, but Runx2 protein was undetectable in BMP-2-treated or empty 









MyoD and myogenin mRNA levels were highest in control cells, and were repressed in 
Runx2-treated samples at day 7, suggesting that Runx2 inhibits myogenesis in these cells.  
In contrast to the effects of Runx2, BMP-2 treatment did not alter the expression of these 
MRFs (p>0.83).  However, mRNA expression of troponin T, a tropomyosin binding 
molecule and common marker of myogenic differentiation downstream of MRFs, was 
downregulated by an order of magnitude by both Runx2 and BMP-2 treatments (data not 
shown).   
Expression of Id-1, a known inhibitor of myogenesis, was high at day 1 and 
decreased in Runx2 transduced cells and controls as differentiation progressed.  
However, Id-1 mRNA levels remained elevated in BMP-2 treated samples at days 3 and 
7, suggesting that Runx2 overexpression and BMP-2 treatment inhibit myogenesis by 
distinct mechanisms.  While Runx2 inhibits expression of MRFs, BMP-2 upregulates 
expression of an inhibitor of MRF activity (Id-1).  This finding could be explained by 
parallel BMP-2-activated signaling pathways distinct from Runx2 transactivation.  
Alternatively, saturating levels of Runx2 may upregulate a repressor of Id-1.  However, 
in cultures treated with both Runx2 and BMP-2, Id-1 levels remained high, showing that 
Runx2 does not repress Id-1 expression, and confirming that Runx2 is only one of several 
downstream targets of BMP-2 signaling.   
Visual inspection by phase contrast microscopy and immunofluorescence staining 
for sarcomeric myosin confirmed the functional significance of these shifts in mRNA 
expression (Fig. 3.2B-C).    Elongated myotubes were clearly visible in empty vector 
control cultures at 7 days post-transduction.  The formation of myotubes was reduced in 
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Figure 3.2.  Runx2 inhibits myogenesis.  (A)  Myogenic gene expression was analyzed at 
1, 3, and 7 days post-transduction by real time RT-PCR (Mean + SEM, n=6).  MyoD 
mRNA levels were repressed in Runx2 cultures at day 7 and co-treated cultures at days 1 
and 7 relative to empty vector controls.  MyoD levels in Runx2 cultures were lower than 
BMP-2 treated cells at day 7.  Myogenin expression was repressed in Runx2 cells relative 
to control cultures at day 7.  Id-1 expression was high at day 1 and decreased with time, 
but remained elevated in BMP-2 treated cells and days 3 and 7.  * different from Empty 
Vector, † different from BMP-2, ‡ different from Runx2 (p<0.05).  (B)  Phase contrast 
micrographs at 21 days post-transduction.  Empty vector cells formed large 
multinucleated myotubes, while BMP-2 and Runx2 treated cells developed a cuboidal 
morphology typical of osteoblast cultures.  (C)  Immunofluorescence staining for 
sarcomeric myosin at 7 days post-transduction.  Elongated multinucleated myotubes were 
present in control cells.  Myotube formation was reduced in BMP-2 treated cultures and 





Runx2 and Runx2/BMP-2 co-treated cultures displayed no multinucleated 
structures.  A fraction of cells remained positive for myosin in Runx2 cultures but were 
rounded and mononucleated, potentially representing non-transduced cells.  Cells treated 
with either Runx2 or BMP-2 for 21 days developed into a cuboidal cobblestone 
morphology, typical of osteoblast cultures103. 
 
Runx2 Upregulates Osteoblastic Gene Expression 
 Osteogenic gene expression was assessed at 1, 3, and 7 days post-retroviral 
transduction.  The markers of osteoblastic differentiation osteocalcin (OCN), alkaline 
phosphatase (ALP), bone sialoprotein (BSP), osterix (OSX), and Dlx5 were analyzed to 
assess the effects of sustained Runx2 expression on osteogenesis in primary skeletal 
myoblasts (Fig. 3.3).  OCN is an extracellular matrix protein and a marker of mature 
osteoblasts, ALP is an osteoblastic metabolic enzyme involved in mineral deposition, and 
BSP is an osteoblastic matrix molecule that is responsible for mineralized nodule 
nucleation104.  OSX is a zinc-finger transcription factor required for bone 
mineralization105 and Dlx5 is an osteoblastic transcription factor shown to accelerate 
osteoblastic differentiation106.  Forced Runx2 expression and BMP-2 treatment resulted 
in upregulated mRNA expression of all five osteogenic genes that generally increased 
with time (note logarithmic scale).  At 7 days, Runx2 overexpression induced greater 
levels of OCN, BSP, OSX, and Dlx5 mRNA compared to BMP-2 treatment.  Co-
treatment of Runx2 and BMP-2 resulted in enhanced effects compared to either treatment 
alone on OCN, BSP, OSX, and Dlx5 expression at early time points.  By 7 days the 
enhanced effect of simultaneous Runx2 and BMP-2 treatment was absent for all genes 
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except Dlx5, suggesting a time dependent increase in the osteogenic activity of both 
treatments that was eventually saturated by high levels of Runx2 in transduced cultures.   
Interestingly, a synergistic effect of co-treatments on Dlx5 expression was present at all 
time points, suggesting Runx2 acts cooperatively with other BMP-2-induced factors or 
the existence of Runx2-dependent and Runx2-independent mechanisms for Dlx5 
upregulation.   Fibronectin and osteopontin, two extracellular matrix proteins produced 
by osteoblasts, were also upregulated by BMP-2 and Runx2 at 7 days post-transduction 
(data not shown).  
BMP-2 is also known to stimulate mesenchymal progenitor cells into 
chondrogenic and adipogenic lineages107,108 and Runx2 has been recently implicated in 
chondrogenesis109.  Therefore we assessed alcian blue staining and Sox9 expression for 
chondrogenesis, and adipsin and PPARγ expression for adipogenesis.  No differences 
were observed for any of these markers amongst treatment groups (data not shown), 
including empty vector controls and unmodified cells, suggesting that the response to 
BMP-2 and Runx2 is specific to osteogenesis in these cells.   
 
Sustained Runx2 Induces Functional Osteogenesis 
 ALP biochemical activity and matrix mineralization were analyzed to assess the 
functional effects of BMP-2 and Runx2-stimulated osteogenic gene expression.  ALP 
enzymatic activity at 7 days was induced by both Runx2 and BMP-2 (Fig. 3.4).  Similar 
to the trends in expression profiles for several osteogenic genes at 7 days, activity in 
Runx2-transduced samples was greater than in BMP-2 treated cells, and the combined 


































































































































Figure 3.3.  Runx2 upregulates osteogenic gene expression.  Osteogenic gene expression 
was evaluated at 1, 3, and 7 days post-transduction by real time RT-PCR (Mean + SEM, 
n=6).  Osteocalcin (OCN), alkaline phosphatase (ALP), bone sialoprotein (BSP), osterix 
(OSX), and Dlx5 were upregulated by BMP-2 treatment and exogenous expression of 
Runx2.  Retroviral Runx2 expression saturated induction at 7 days for all genes but Dlx5, 
which showed a synergistic increase in expression with Runx2 and BMP-2 co-treatment.  

































































Figure 3.4.  Runx2 stimulates alkaline phosphatase biochemical activity.  ALP activity 
was assessed at 7 days post-transduction (Mean + SEM, n=3).  ALP activity was 
undetectable above background in control cells but was upregulated in response to BMP-
2.  Forced Runx2 expression induced ALP activity levels above controls and BMP-2 
samples, and co-treatment with Runx2 and BMP-2 was equivalent to Runx2 alone.  * 











was used as a marker of matrix mineralization at 14 and 21 days post transduction (Fig. 
3.5A).  Empty vector control cultures exhibited no mineral deposition, and Runx2-treated 
samples displayed strong positive stains for phosphate deposits similar to that of MC3T3-
E1 premature osteoblasts used as positive controls (data not shown).  BMP-2 treated 
samples developed a light hazy stain, and sparse mineralized nodules were detectable at 
higher magnifications (Fig. 3.5B).  FTIR spectroscopy was used to analyze the chemical 
composition of the mineral phase in cultures at 21 days post-transduction as well as 
explanted bone from rat cranium (Fig. 3.5C).  Absorption bands representing organic 
components in the extracellular matrix and lipid content were present in all samples at 
1655 cm-1 (Amide I, C=O), 1550 cm-1 (Amide II, N-H and C-N), 1460 cm-1 (CH2), 1380 
cm-1 (CH3),  and 1240 cm-1 (C-N and N-H)110.  Bands at 710 and 760 cm-1 coincide with 
aromatic hydrocarbon peaks of a polystyrene standard, representing residual tissue 
culture plastic in the sample from the harvest procedure.  Runx2 and cranial bone 
samples displayed an enhanced peak at 1100 cm-1 (P-O), as well as additional peaks at 
870 cm-1 (C-O) and a split peak at 600 cm-1 (P-O), representing the characteristic bands 
of a carbonate-containing, poorly crystalline hydroxyapatite110.  These additional bands 
were absent in empty vector cultures and barely detectable in BMP-2 treated samples, 
likely due to minimal mineral deposition as visualized by the von Kossa staining.  
Samples treated with both Runx2 and BMP-2 produced spectrograms similar to that of 
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Figure 3.5.  Runx2 induces mineral deposition. (A) Matrix mineralization was assessed 
by von Kossa staining for phosphate deposits at 14 and 21 days post-transduction (Mean 
+ SEM, n=6).  Controls contained no stained regions and BMP-2 treatment produced a 
light hazy stain.  Runx2 and co-treated samples developed densely mineralized regions 
and heavy stains.  Stains were quantified by automated capturing and averaging of 
twenty-four representative 2X images.  * different from Empty Vector, † different from 
BMP-2 (p<0.05).  Scale bar indicates 10 mm.  (B) Sparse nodules were detectable by 
higher magnification in BMP-2 treated samples.  Scale bar indicates 300 µm.  (C) 
Chemical composition of the mineral phase was analyzed by FTIR spectroscopy.  
Adsorption bands at 1655 cm-1 (Amide I, C=O), 1550 cm-1 (Amide II, N-H and C-N), 
1460 cm-1 (CH2), 1380 cm-1 (CH3),  and 1240 cm-1 (C-N and N-H) represent bonds in the 
extracellular matrix and lipid content.  Runx2 and cranial bone samples displayed an 
enhanced peak at 1100 cm-1 (P-O), as well as additional peaks at 870 cm-1 (C-O) and a 
split peak at 600 cm-1 (P-O), representing the characteristic bands of a carbonate-
containing, poorly crystalline hydroxyapatite.  These additional bands were absent in 
empty vector cultures, and were barely visible in BMP-2 treated samples, likely due to 
minimal mineral deposition as detected by von Kossa staining.  Samples treated with both 
Runx2 and BMP-2 produced spectrograms similar to that of Runx2 alone.   
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BMP-2 Induces Negative Regulators of Osteogenesis 
 These results show that Runx2 induces osteoblastic gene expression, enzyme 
activity, and biological mineralization to higher levels than treatment with the osteogenic 
growth factor BMP-2.  Based on these results, we hypothesized that direct forced 
expression of Runx2 bypasses several upstream stages of BMP-2 induced control of the 
osteogenic response.  To test this hypothesis, we examined the expression profiles of 
several osteogenic activators and repressors upstream of Runx2-dependent transcription 
(Fig. 3.6).  Noggin, an inhibitor of BMP-2 activity, was unaffected by Runx2, but was 
upregulated by BMP-2 at 7 days.  Noggin was also upregulated in cultures treated 
simultaneously with BMP-2 and Runx2.  Smad6, an inhibitor of BMP-2 signaling 
through its activated receptor, and Msx2, a direct inhibitor of Runx2 activity, were 
upregulated by Runx2 relative to empty vector controls, but expression increased to 
greater levels with BMP-2 treatment.  HES-1, which increases Runx2 activity, was 
unaffected by Runx2 but was downregulated by BMP-2, and Runx2 rescued the BMP-2 
induced suppression in co-treated samples.  These results suggest that direct forced 
expression of Runx2 bypasses parallel signaling pathways stimulated by BMP-2 that 
mediate the subsequent osteogenic response to this growth factor.  
 
Discussion 
Transdifferentiation has been defined as “the conversion of a cell of one tissue 
lineage into a cell of an entirely distinct lineage, with concomitant loss of the tissue-
specific markers and function of the original cell type, and acquisition of markers and 










































































Figure 3.6.  Forced expression of Runx2 bypasses BMP-2 stimulated regulatory control 
of osteogenesis.  Regulatory gene expression was evaluated at 7 days post-transduction 
by real time RT-PCR (Mean + SEM, n=6).  Noggin expression was induced by BMP-2 
but was unaffected by Runx2.  Smad6 and Msx2 were induced by Runx2 relative to 
controls, but to even greater levels by BMP-2.  Co-treatment with Runx2 and BMP-2 did 
not alter the levels of noggin, Smad6, or Msx2 expression relative to BMP-2 alone.  HES-
1 was downregulated by BMP-2 but not Runx2, and Runx2 rescued the BMP-2 induced 
suppression in co-treated cells.  * different from Empty Vector, † different from BMP-2, 






desmin positive, a common marker of myoblastic cell fate, and <5% positive for CD34 or 
Sca-1 (data not shown), markers of stem cell populations present in muscle tissue61.  
Additionally, these cells have previously been shown to be >99% myogenic100.  Runx2 
overexpression in skeletal myoblasts resulted in the loss of myoblastic markers MyoD 
and myogenin as well as myotube formation.  These cells also gained several osteogenic 
markers, and more importantly the osteoblastic function of matrix mineralization, 
demonstrating Runx2-stimulated transdifferentiation.  Furthermore, we have observed 
similar myogenic inhibition and osteoinduction, including mineralization, in Runx2-
overexpression experiments with the clonal C2C12 myogenic cell line (unpublished 
results), providing additional evidence for transdifferentiation.   
 The osteoinductive effects of BMP-2 on non-osteoblastic cell types are well 
documented.  However, the BMP signaling cascade is remarkably elaborate, involving 
the coordinated function of numerous ubiquitous signaling molecules including 
extracellular matrix proteins112, Smads7, protein kinase D113, protein kinase C114, and 
mitogen-activated protein kinases (MAPKs)115-120.  Therefore it is particularly noteworthy 
that the exogenous expression of a single transcription factor downstream of the many 
regulators of BMP signaling is capable of reprogramming a committed myogenic cell 
type into an osteoblastic differentiation cascade.  Additionally, forced expression of 
Runx2 had a more potent osteogenic effect than BMP-2 treatment, which may be 
explained by several hypotheses.  First, we have shown that BMP-2 concomitantly 
positively and negatively regulates osteogenesis, resulting in a less potent signal, whereas 
Runx2 overexpression may serve as a more specific osteogenic stimulus.  Therefore, the 
greater osteogenic effect of Runx2 may, in part, be the result of bypassing upstream 
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regulatory mechanisms by targeting a transcriptional activator downstream of the growth 
factor signaling pathway.  Also, Huard and colleagues have identified a subpopulation of 
BMP-2 sensitive muscle derived stem cells in myoblast isolates58,61.  The cells used in the 
present study may contain a similar subpopulation, resulting in osteogenic induction in 
only a fraction of the cells.  This would result in a reduced amount of osteogenic gene 
expression and alkaline phosphatase activity, and sparse mineralization, as observed here.  
In addition, this study uses recombinant BMP-2 expressed in E. coli.  BMP-2 is a highly 
glycosylated protein and proper mammalian post-translational modifications may result 
in a more potent effect.  Additionally, we used 300 ng/ml of BMP-2 as a reference to the 
vast amount of literature evaluating BMP-2 function at this concentration, but this dosage 
does not necessarily saturate BMP-2 signaling.   
The differential expression of Id-1, noggin, Smad6, Msx2, and HES-1 in response 
to BMP-2, Runx2, and Runx2 and BMP-2 co-treatments, demonstrate that there are 
several other factors involved in the regulation of this complex process and that BMP-2 is 
serving functions in addition to Runx2-dependent osteogenesis in this system.  In 
addition to the negative regulation of osteogenesis mentioned above, Runx2 has been 
reported to autoregulate its own expression121.  Therefore, BMP-2-induced Runx2 is 
capable of self-regulation, whereas the retroviral system drives expression from a viral 
promoter which acts independently of endogenous osteogenic repression and activation 
mechanisms.  This results in the greater levels of Runx2 mRNA in transduced cultures 
relative to BMP-2 treatment and represents another control of BMP-2 induced 
osteogenesis.  It is also important to note that these shifts in mRNA levels do not 
necessarily reflect the magnitude of protein expression and activity, as many genes, 
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including Runx2, are subject to translational regulation and post-translational protein 
modification and regulation122.  Runx2 expression and activity can also respond to other 
pathways, such as signaling by extracellular matrix proteins, MAPKs, fibroblast growth 
factor-2, mechanical loading, parathyroid hormone, and tumor necrosis factor-α112,123-127.   
 Previous work demonstrated that transient expression of Runx2, via 
transfection11, adenoviral transduction56,78, or TGF-β signaling14, is not sufficient for 
conversion of non-osteogenic cells into an osteoblastic phenotype.  In the present study, 
using retroviral transduction, a constitutive Runx2 gene was integrated and expressed at 
high levels for 21 days in vitro.  This sustained expression was sufficient for conversion 
into an osteoblastic phenotype.  Previous reports demonstrate that although both BMP-2 
and TGF-β induce Runx2 expression in the C2C12 myogenic cell line, only BMP-2 
upregulates cofactors necessary for osteoblastic conversion, namely Dlx533.  Lee et al. 
have also shown that Dlx5 antisense can block BMP-2-induced Runx2 expression and 
osteoblastic conversion, but not TGF-β-induced Runx2 expression.  Dlx5 expression was 
still induced by BMP-2 in Runx2 knockout murine fetal calvarial cells, suggesting that 
Runx2 does not play a role in Dlx5 expression128.  In addition, Lee et al. have shown that 
Dlx5 can upregulate OSX expression independent of Runx2 by transfecting Dlx5 into 
Runx2 knockout cells.  These observations have led to a proposed model of a linear 
signaling cascade initiated with Smad1/5 activation, followed by Dlx5 expression, 
resulting in independent upregulation of Runx2 and OSX128.  However, this model is not 
consistent with the present results.  We demonstrate that Runx2 upregulates both Dlx5 
and OSX, and co-treatment with BMP-2 and Runx2 results in a synergistic effect on Dlx5 
expression.  Taken together with these previous results, the current findings establish 
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Runx2-dependent and -independent pathways for Dlx5 and OSX expression.  This 
suggests that the observed osteogenesis induced by these transcription factors is not 
simply defined by a linear signaling cascade, but rather a complex model composed of 
multiple feedback loops.  This model is further strengthened by evidence that exogenous 
expression of one of the constituents of this cycle results in upregulation of other cycle 
members. 
Osteoblastic differentiation represents a complex process involving numerous 
signaling cascades which synergize to direct the high order functions of matrix 
mineralization and bone formation.  We have replicated several osteoblastic markers and 
functions in skeletal myoblasts using forced expression of Runx2.  However, not all 
elements of osteoblasts are represented in these cells, as demonstrated in this study by the 
absence of regulatory factors such as noggin.  Previous studies have identified distinct 
differences in the chemical and biological makeup of mineralized matrix produced in 
vitro by osteoblasts from different sources129,130.  This result is not suprising given the 
wide range of practices involved in cell line development, primary cell isolation and 
purification, and culturing conditions.  Using FTIR spectroscopy, we have identified the 
mineralized matrix produced by Runx2 overexpressing primary myoblasts as a carbonate 
containing, poorly crystalline apatite, similar to that produced by primary osteoblast 
cultures130.  
In conclusion, we have demonstrated Runx2-induced mineralization and 
functional osteogenesis in primary skeletal myoblasts.  This work suggests that sustained 
Runx2 expression is necessary for conversion into an osteoblastic phenotype and that 
Runx2 regulates other transcriptional activators critical to osteoinduction, including Dlx5 
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and OSX.  These results assist in elucidating the function of Runx2 in osteogenesis and 
its role in BMP-2 signaling.  This work also provides insights into the plasticity of 
committed mesenchymal cells and supports the potential of Runx2-induced osteogenesis 




RUNX2-GENETICALLY ENGINEERED SKELETAL MYOBLASTS 
MINERALIZE COLLAGEN SCAFFOLDS IN VITRO* 
 
Introduction 
 Orthopaedic reconstructions have a significant socioeconomic impact worldwide, 
as evidenced by the 2.2 million operations requiring bone substitutes each year4.  Existing 
bone substitutes include autografts, allografts, and synthetic materials35,36.  Autografting 
involves the harvest of autogenous bone, typically from the iliac crest, for implantation 
into an osseous defect.  Although successful in many cases, this procedure is limited by 
the availability of healthy tissue, donor site morbidity, and pain associated with the 
harvest4,36.  Allografts, typically cadaver bone from bone banks, suffer from reduced 
biological and mechanical properties after processing and possible disease transmission4.  
Synthetic materials, including titanium, ceramics, and synthetic hydroxyapatite, generally 
incite host inflammation and fail to adequately integrate and remodel with the 
surrounding native tissue37.  Bone tissue engineering has emerged as a promising 
alternative to these strategies.  The general paradigm of these approaches focuses on 
incorporating cells, a scaffold, and bioactive factors into an implantable construct38,39.  
Current applications of bone tissue engineering have been hindered by availability 
of a sustained, mineralizing cell source that can generate mechanically robust constructs 
for large defects.  Terminally differentiated osteoblasts, the cells responsible for bone 
* Modified from 
C.A. Gersbach, B.A. Byers, G.K. Pavlath, R.E. Guldberg, and A.J. Garcia, Runx2/Cbfa1-Genetically 




formation, are difficult to obtain in large numbers and fail to proliferate and substantially 
populate typical tissue-engineered constructs.  Immortalized osteogenic cell lines have 
the potential to form tumors in vivo.  Osteogenic precursors, such as bone marrow 
stromal cells, are capable of osteoblastic differentiation and mineralization40, and have 
been used in many cases to successfully heal bone defects41-46.  However, these cells are 
also difficult and painful to obtain in suitable quantities38, typically de-differentiate and 
lose phenotype following in vitro culture and expansion47-49, and demonstrate an age-
related decrease in osteogenic capacity50.  A promising alternative to these cell sources is 
the induction of sustained osteogenesis in non-osteoblastic cells using genetic 
engineering approaches.   
Bone morphogenetic proteins (BMPs) have been used extensively to induce 
osteogenesis in non-osteoblastic cell types, including bone marrow stromal cells51-54, 
dermal and gingival fibroblasts55,56, and skeletal myoblasts13,57.  BMP growth factors act 
extracellularly by binding to transmembrane receptors, inducing an intracellular signaling 
cascade7,8.  BMP signaling upregulates the osteoblastic transcriptional activator 
Runx2/Cbfa1, which acts as a scaffold for several other transcriptional regulators and 
accessory factors, including Smads9-11, Cbfβ131, TLE/Groucho34, HES-129, and AP-1 
factors132.  This composite transcriptional apparatus regulates osteoblastic gene 
expression and functional osteogenesis20,24,133.  Runx2 is required for osteoblastic 
differentiation as well as endochondral and intramembranous bone formation20,21.  
Heterozygous mutation of the Runx2 gene is implicated in the human skeletal disorder 
cleidocranial dysplasia22,23, and the homozygous mutation in mice causes immediate 
postnatal death21.   
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Skeletal myoblasts have been used extensively in combination with BMPs to 
generate bone tissue in both ectopic and osseous environments.58-60  The positive results 
of these BMP-based gene therapy strategies with skeletal myoblasts led to our hypothesis 
that sustained forced expression of Runx2, a downstream regulator of BMP signaling, 
will stimulate transdifferentiation of primary skeletal myoblasts into a mineralizing 
osteoblastic phenotype.  Primary skeletal myoblasts represent a clinically relevant 
autologous source of mesenchymal progenitor cells that are readily accessible in large 
quantities from muscle biopsies.  They are easily purified and expanded under the 
appropriate culture conditions and contain a subpopulation of muscle-derived stem 
cells61.  Furthermore, the use of autologous cells in a clinical setting avoids 
immunological complications involved in allogeneic and xenogeneic cell-based 
strategies.  Myoblasts are also compatible with gene transfer technologies and achieve 
high levels of transduction by viral gene therapy62.  
In the present study, we demonstrate that Runx2-genetically engineered skeletal 
myoblasts are a promising cell source for osteoblastic matrix production and in vitro 
mineral deposition on collagen scaffolds.  These results are significant in overcoming 
several limitations of cell-based therapeutic and tissue engineering strategies for the 
treatment of large osseous defects.    
 
Materials and Methods 
Cell Culture 
 Primary myoblasts were isolated from the tibialis anterior muscles of adult male 
Balb/c mice and cultured in selective growth media (Ham’s F10, 20% fetal bovine serum, 
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5 ng/ml bFGF (Promega, Madison, WI), 100 U/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate), yielding cultures that are greater than 99% desmin positive100.  
Cells were cultured on tissue culture plastic dishes coated with 0.01% type I collagen 
(Cohesion, Palo Alto, CA) in a humidified 5% CO2 atmosphere at 37 ºC.  Cell culture 
media and antibiotics were obtained from Invitrogen (Carlsbad, CA), fetal bovine serum 
was purchased from Hyclone (Logan, UT), and all other reagents were acquired from 
Sigma (St. Louis, MO). 
 
Retroviral Transduction 
The Runx2 retroviral vector24 uses the promoter activity of the 5’ long terminal 
repeat (LTR) to express a single bicistronic mRNA encoding the murine cDNA for the 
type II MASNSLF Runx2 isoform101,102,134, followed by an internal ribosomal entry site 
(IRES) and a zeocin resistance-enhanced green fluorescent protein fusion protein 
(Zeo:eGFP), allowing for noninvasive detection of transduction efficiency.  Plasmid 
DNA was purified from transformed E. coli using plasmid megaprep kits from Qiagen 
(Valencia, CA).  Retroviral stocks were produced by transient transfection of helper-virus 
free ΦNX amphotropic producer cells with plasmid DNA as previously described24.  
Briefly, ΦNX cells were cultured in growth media (DMEM, 10% fetal bovine serum, and 
100 U/ml penicillin G sodium, 100 µg/ml streptomycin sulfate) in a humidified 5% CO2 
atmosphere at 37 °C and plated at 9 x 104 cells/cm2 24 hours prior to transfection.  Cells 
were transfected with 0.5 µg/cm2 of plasmid DNA, either Runx2 or control vector (no 
Runx2 insert), using calcium phosphate coprecipitation and 25 µM chloroquine for 8-12 
hours prior to refeeding with fresh growth media.  Twenty-four hours after the start of the 
 
 48
transfection, media was replaced with fresh growth media and cultures were transferred 
to a humidified 5% CO2 atmosphere at 32 °C for enhanced stability of retroviral particles.  
Retroviral supernatants were collected at 48, 60, and 72 hours post-transfection, filtered 
through a 0.45 µm cellulose acetate filter, aliquoted, snap frozen, and stored at -80 °C 
until use. 
  Primary myoblasts were cultured up to 12 passages and plated on 0.01% collagen-
coated tissue culture polystyrene at 2 x 104 cells/cm2 24 hours prior to retroviral 
transduction62.  Cells were transduced with 0.2 ml/cm2 of retroviral supernatant 
supplemented with 4 µg/ml hexadimethrine bromide (Polybrene), 5 ng/ml bFGF, and 
10% fetal bovine serum, and centrifuged at 2500 rpm (1200 g) for 30 minutes in a 
Beckman model GS-6R centrifuge with a swinging bucket rotor.  After transduction, 
growth media was reapplied, and cultures were returned to 37°C and transduced again 
12-16 hours later in order to increase transduction efficiency.  Control vector (no Runx2 
insert) retrovirus served as a negative control for all experiments.  After the final 
transduction, retroviral supernatants were replaced with growth media.  Retrovirally 
transduced cells were analyzed for eGFP expression by fluorescence microscopy and 
flow cytometry, using a Becton-Dickinson FACS Vantage SE Cell Sorter.  Unmodified 
cells were used to monitor autofluorescence.  High levels of eGFP were detected in 51 ± 
2% of Runx2-engineered cells and 60 ± 1% of control cells by flow cytometry at 72 
hours post-transduction, and no selection protocols were performed to isolate transduced 






 Fibrous collagen disks (8 mm x 1.5 mm, Kensey Nash, Exton, PA) were 
incubated overnight in 10% FBS in phosphate buffered saline (PBS).  The average pore 
size of these scaffolds was 61.7 µm with a 93.7% pore volume, as measured by mercury 
porosimetry.  Forty-eight hours after the second transduction, 500,000 cells in 25 µl of 
growth media were seeded onto each side of the disk in a non-tissue culture treated 24 
well plate.  Four hours later, scaffolds were immersed in 2 ml of growth media.  After 
twenty-four hours, scaffolds were transferred to non-tissue culture-treated 12 well plates 
in 4 ml of differentiation media (αMEM, 10% fetal bovine serum, 100 U/ml penicillin G 
sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid and 3 mM sodium β-
glycerophosphate).  Media was replaced every three days until terminal assay. 
 
Cell Viability 
 Scaffolds were rinsed in PBS and incubated in 4 µM calcein AM and 4 µM 
ethidium homodimer-1 (Molecular Probes, Eugene, OR) in PBS for 30 minutes under 
gentle agitation.  After incubation, scaffolds were rinsed (3 x 10 min) in PBS and 
analyzed with a Zeiss LSM 510 Confocal Microscope using Ar and HeNe lasers and a 5X 
objective lens.  The eGFP signal from cells not loaded with calcein was undetectable by 
confocal microscopy at this low magnification.  Images acquired from scaffolds seeded 
with unmodified cells were similar to those of genetically modified cells, confirming that 
green fluorescence observed by confocal microscopy was due to the presence of calcein, 





 Constructs were rinsed with PBS and frozen at -80°C at 1, 21, and 42 days post 
scaffold seeding.  Scaffolds and serially diluted cell standards were thawed, lyophilized, 
and digested at 60°C in 500 µl of 0.25 mg/ml proteinase K (Fisher Scientific) in 100 mM 
ammonium acetate (pH 7.0) for 24 hours.  Digested samples were assessed for DNA 
content with the PicoGreen dsDNA Quantitation Kit (Molecular Probes).  Raw data were 
converted to cell number using a linear standard curve.   DNA content of scaffolds seeded 
with genetically modified cells was similar to that of scaffolds seeded with unmodified 
cells, confirming that proteinase K digestion of eGFP ablated any residual endogenous 
fluorescence. 
 
Real Time RT-PCR 
Total RNA was isolated at 7 and 21 days post scaffold seeding using the RNeasy 
isolation kit with RNAlater stabilization reagent (Qiagen).  cDNA synthesis was 
performed on DNaseI-treated (27 Kunitz units/sample) total RNA (0.5 µg) by oligo(dT) 
priming using the Superscript™ First Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA).  Real-time PCR using SYBR Green intercalating dye was performed with 
the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) 
(40 cycles, melting: 15 sec at 95ºC, annealing and extension: 60 sec at 60ºC)24.  Real-time 
PCR oligonucleotide primers were designed using ABI Primer Express software and 
purchased from IDTDNA (Coralville, IA).  Primer specificity was confirmed by agarose 
gel electrophoresis and ABI Prism 7700 Dissociation Curve Software.  Runx2 (Accession 
# NM_009820) primer sequences were 5’- GGCCTTCAAGGTTGTAGCCC -3’ 
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(forward) and 5’- CCCGGCCATGACGGTA -3’ (reverse); myoD (Accession # 
XM_124916) primers were 5’-CGGCTACCCAAGGTGGAGAT-3’ (forward) and 5’-
ACCTTCGATGTAGCGGATGG-3’ (reverse); myogenin (Accession # NM_031189) 
primers were 5’-CTGACCCTACAGACGCCCAC-3’ (forward) and 5’-
TGTCCACGATGGACGTAAGG-3’ (reverse); troponin T (Accession # AJ131711) 
primer sequences were 5’-TCAATGTGCTCTACAACCGCA-3’ (forward) and 5’- 
ACCCTTCCCAGCCCCC-3’ (reverse).  All other primer sequences have been described 
previously24.  Standards for each gene were amplified from cDNA using real-time 
oligonucleotides, purified using a Qiagen PCR Purification kit, and diluted over a 
functional range of concentrations.  Transcript concentration in template cDNA solutions 
was quantified from a linear standard curve and normalized to 1 µg of total RNA.  
Detection limits for each gene were determined by reactions without cDNA and are 
represented by dotted lines where applicable.  
 
Micro-computed Tomography 
In vitro mineralization of 3-D scaffolds was quantified by high resolution X-ray 
micro-computed tomography (micro-CT) using a Scanco Medical µCT 40 imaging 
system (Bassersdorf, Switzerland).  Specimens were scanned in formalin at 16 µm voxel 
resolution and evaluated at a threshold corresponding to a linear attenuation of 0.88 cm-1, 
filter width of 1.2, and filter support of 2.0.  The reconstructed and thresholded 3-D 
images were evaluated using direct distance transformation methods to calculate 





 Formalin-fixed constructs were paraffin embedded, and 5 µm sections were 
stained with hematoxylin-eosin to observe cellular distribution or von Kossa-nuclear fast 
red to detect phosphate deposits in the 3-D collagen scaffolds. 
 
FTIR Spectroscopy 
 Scaffolds at 42 days post-transduction were fixed in 100% ethanol and dried at 
50ºC overnight.  Bone samples were scraped from a lyophilized rat cranium and used as a 
positive control.  Bulk samples were mixed with KBr (Sigma) and pressed into pellets.  
Samples were analyzed with a Nicolet Nexus 470 Fourier transform infrared (FTIR) 
spectrometer (ThermoNicolet, Madison, WI) equipped with a DTGS detector.  Sixty-four 
scans were acquired at 4 cm-1 resolution under N2 purge.  
 
Mechanical Testing 
 Scaffolds were rinsed in PBS, measured for height and diameter, submerged in 
PBS, and analyzed by unconfined compression with solid platens at 0.15 mm per minute 
after preloading with 0.02 N, with a DDL Info 650R uniaxial electromechanical testing 
system (TestResources, Shakopee, MN).  Stress-strain data were determined from load 
and displacement measurements after normalization by area and height, respectively.  
Stress-strain curves were characterized by a toe-in region, followed by a linear elastic 
segment, before a distinct failing region.  Compressive modulus was determined by the 
slope of the linear elastic region of the stress-strain curve from immediately after the toe-





All analyses were performed in triplicate in independent experiments conducted at 
least two times, each with unique Runx2 retroviral supernatant preparations and two 
independent isolates of primary skeletal myoblasts.  No differences were observed 
between unmodified and control vector transduced cells for all assays.  Data are reported 
as mean ± standard error of the mean (SEM), and statistical comparisons using SYSTAT 
8.0 were based on an analysis of variance (ANOVA) and Tukey’s test for pairwise 
comparisons with a p-value less than 0.05 considered significant.  In order to evaluate the 
variance independent of the mean, statistical analysis of real-time RT-PCR data was 
performed following logarithmic transformation of the raw data24. 
 
Results 
Cellular Viability  
 DNA content was assessed at 1, 21, and 42 days post-seeding to determine 
seeding efficiency and cell numbers throughout the culture period (Fig. 4.1A).   No 
differences between Runx2-engineered and control cultures were observed at any time 
point.  Approximately 450,000 cells were present on scaffolds at 1 day, corresponding to 
a cell seeding efficiency of 44.8 ± 1.5%.  DNA content decreased with time for both 
treatments, possibly due to the removal of nonadherent cells still present in the scaffolds 
at earlier time points or cell death resulting from mass transfer limitations after matrix 
and mineral deposition at the surface of the mature construct.  Nevertheless, significant 








Figure 4.1.  Cell number and viability on collagen scaffolds.  (A) DNA content was used 
to evaluate cell number over culture time (mean + SEM, n=6).  Approximately 450,000 
cells were present on scaffolds 1 day post-seeding, representing a seeding efficiency of 
44.8 ± 1.5%.  DNA content decreased with time, although large numbers of cells were 
still present after six weeks of in vitro culture.  * different from 1 Day (p<2E-5). † 
different from 21 Days  (p<0.004). (B) Live/dead staining confirmed cell viability at the 
construct periphery at all time points.  Cells were rounded at 1 day and were spread and 





Cell viability was assessed by Live/Dead fluorescence staining throughout six 
weeks of culture and no differences were evident between treatments (Fig. 4.1B).   Dense 
cell populations were present at the construct surface at all time points.  At one day post-
seeding cells were rounded, but at later time points they were spread and confluent.  
Minimal cell death (<10%) was observed throughout the constructs, as determined by 
ethidium incorporation, although few isolated small necrotic regions were present.     
 
Osteogenic and Myogenic Gene Expression 
 Osteogenic and myogenic gene expression was analyzed via real-time RT-
PCR at 7 and 21 days post seeding (Fig. 4.2).  Runx2 expression was upregulated 10- and 
100-fold in transduced cultures at 7 and 21 days, respectively.  Alkaline phosphatase 
(ALP) is an enzyme responsible for phosphate precipitation and mineral incorporation104.  
Osteocalcin (OCN), bone sialoprotein (BSP), and collagen α1 (I) (COLα1(I)) are 
osteoblastic extracellular matrix molecules present in bone and markers of osteoblastic 
differentiation104.  Runx2 overexpression significantly upregulated all four of these 
osteoblastic markers by as much as 10,000-fold relative to controls.  MyoD and 
myogenin are transcriptional activators that belong to the family of myogenic regulatory 
factors (MRFs).  MyoD determines myoblastic cell fate, and myogenin acts downstream 
of MyoD by regulating commitment to myogenic differentiation17.  Expression of both of 
these MRFs was downregulated by Runx2 overexpression.  Troponin T, a tropomyosin 
binding molecule and common marker of myogenic differentiation downstream of MRFs, 
was also repressed by Runx2.  Shifts in mRNA expression were detectable as early as one 






























































































Figure 4.2.  Runx2 induces osteogenic and represses myogenic gene expression in 
skeletal myoblasts cultured in 3-D collagen scaffolds.  Gene expression was analyzed at 7 
and 21 days post-transduction by real time RT-PCR (mean + SEM, n=6).  Runx2 
upregulated the expression of osteoblastic genes osteocalcin (OCN), alkaline phosphatase 
(ALP), bone sialoprotein (BSP), and collagen α1 (I) (COLα1(I)).  Runx2 downregulated 
myogenic gene expression, including MyoD, myogenin, and troponin T.  * different from 






retroviral vector24.  These results demonstrate that forced expression of Runx2 in skeletal 
myoblasts induces osteoblastic gene expression and represses the myogenic phenotype in 
three-dimensional culture.   
Runx2 has also been implicated in chondrogenesis109, and muscle derived cells 
are capable of both chondrogenic107 and adipogenic136 pathways.  Therefore we assessed 
alcian blue staining and Sox9 expression for chondrogenesis, and adipsin and PPARγ 
expression for adipogenesis in monolayer culture (data not shown).  No differences were 
observed for any of these markers amongst treatment groups, including empty vector 
controls and unmodified cells, suggesting that the response to Runx2 is specific to 
osteogenesis in these cells.   
 
Mineral Deposition and Cellular Distribution 
 Mineral deposition on collagen scaffolds was quantified by microCT at 21 and 42 
days post-seeding (Fig. 4.3).  Mineralized regions were detected primarily on the sides of 
the scaffold at 21 days, and mineralization spread to the face of the constructs by 42 days.  
Mineralization was confined to the periphery of the scaffolds (Fig. 4.4B), which is typical 
of constructs cultured under static conditions due to limitations in mass transport of 
nutrients and waste products.  No mineralization was detectable in constructs seeded with 
control myoblasts. 
 Histological analyses were used to evaluate cellular distribution and matrix 
mineralization throughout the scaffold.  Staining by von Kossa revealed mineralized 
regions on the sides of the construct containing Runx2-modified cells at 21 days, and 
















































Figure 4.3.  Runx2-expressing skeletal myoblasts deposit mineralized matrix on collagen 
scaffolds.  Mineralized regions on tissue-engineered constructs were detected by 
microCT (mean + SEM, n=6).  Control myoblasts demonstrated no mineral deposition.  
Mineralization initiated on the sides of the collagen disk, as seen at 21 days, and spread to 








Regions positive for von Kossa staining were confined to the outer 100-200 µm of the 
scaffold.  No von Kossa staining was evident on scaffolds seeded with control cells.  
Hematoxylin-eosin staining at 42 days showed dense cell populations only at the 
periphery of constructs seeded with both Runx2-modified and control cells, indicating 
that cells were unable to penetrate or survive in the construct interior (Fig. 4.4C). 
 FTIR spectroscopy was used to analyze the chemical composition of the mineral 
phase in scaffolds at 42 days post-transduction (Fig. 4.5).  Explanted bone from rat 
cranium was used as a control.  Absorption bands representing peptide bonds in the 
collagen scaffold and deposited extracellular matrix were present in all samples at 1655 
cm-1 (Amide I, C=O) and 1550 cm-1 (Amide II, N-H and C-N)110.  Runx2 and cranial 
bone samples displayed an enhanced peak at 1100 cm-1 (P-O), as well as an additional 
peak at 870 cm-1 (C-O) and a doublet at 600 cm-1 (P-O), representing the characteristic 
bands of a carbonate-containing, poorly crystalline hydroxyapatite, the mineral phase of 
bone110.  These additional bands were absent in control cultures. 
Mechanical compression testing at 42 days post-seeding was used to determine 
the contribution of the mineral phase to the mechanical integrity of the constructs (Fig. 
4.6).  Scaffolds seeded with Runx2-treated cells exhibited an elastic modulus of 78.0 ± 
12.8 kPa, a 30-fold increase over control scaffolds.   
 
Discussion 
 This work demonstrates the ability of Runx2-overexpressing primary skeletal 
myoblasts to form three-dimensional mineralized tissue-engineered constructs in vitro.  







Figure 4.4.  Histological analysis of cell-seeded collagen scaffolds.  (A) Phosphate 
deposits in the mineralized matrix were visualized by von Kossa-nuclear fast red staining.  
von Kossa positive regions were isolated to the periphery of the scaffold.  Scale bar = 1 
mm.  (B)  Cross sections of reconstructed microCT images of Runx2-engineered 
constructs at 21 and 42 days post-seeding, demonstrating mineralization confined to the 
borders of the scaffold and corroborating von Kossa staining.  (C)  Hematoxylin-eosin 
(H&E) staining at 42 days assessed cellular distribution in the construct.  Cells (purple) 
were present at the edge of the scaffold, and did not penetrate into the interior of the 

























Figure 4.5.  Chemical composition of the mineral phase was analyzed by FTIR 
spectroscopy.  Adsorption bands at 1655 cm-1 (Amide I, C=O) and 1550 cm-1 (Amide II, 
N-H and C-N) represent bonds in the extracellular matrix and lipid content.  Runx2 and 
cranial bone samples displayed an enhanced peak at 1100 cm-1 (P-O), as well as 
additional peaks at 870 cm-1 (C-O) and a split peak at 600 cm-1 (P-O), representing the 
characteristic bands of a carbonate-containing, poorly crystalline hydroxyapatite.  These 













































Figure 4.6. Mechanical compression testing of cell-seeded scaffolds.  Constructs were 
compressed in PBS using a DDL Info 650R electromechanical testing system.  (A) 
Representative raw data recorded as load versus position.  (B)  Raw data was normalized 
by construct area and height to determine elastic modulus (mean + SEM, n=9).  Runx2 
scaffolds exhibited a modulus of approximately 78.0 ± 12.8 kPa, a 30-fold increase over 
controls.  * different from control (p<4E-5).    
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collagen scaffolds, upregulated osteogenic gene expression, downregulated myogenic 
gene expression, and deposited mineralized regions of hydroxyapatite at the periphery of 
the constructs, as detected by microCT, histological analysis, and FTIR spectroscopy.  
Cell distribution was confined to the construct periphery (~100-200 µm), a common 
phenomena associated with transport limitations of static in vitro culture137-139.  Mineral 
deposition typically occurred on only one face of the collagen scaffold at 42 days post-
seeding, potentially due to scaffold processing artifacts or cell localization as a result of 
the static cell seeding protocol.  Although the mineral deposition was localized to the 
periphery, it was still sufficient to improve the mechanical integrity of the constructs 30-
fold.  While the elastic modulus of these mineralized constructs was several orders of 
magnitude below that of native trabecular bone (~80 MPa), optimization of this system, 
including dynamic culture conditions, may improve both the distribution of mineralized 
matrix and mechanical properties of the constructs.   
Osteoblastic differentiation represents a complex process involving numerous 
signaling cascades which synergize to direct the high order functions of matrix 
mineralization and bone formation.  We have replicated several osteoblastic markers and 
functions in skeletal myoblasts using forced expression of Runx2.  However, not all 
required elements for physiological bone formation are present in these in vitro cultures.  
This is evident by the absence of osteoid and the morphological features of native 
lamellar bone tissue in the histological analysis in Figure 4.4 and other studies assessing 
the in vitro maturation of tissue engineered constructs seeded with a mineralizing cell 
source140,141.  Previous studies have also identified distinct differences in the chemical 
and biological makeup of von Kossa-positive material and mineralized matrix produced 
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in vitro by osteoblasts from different sources129,130.  This result is not surprising given the 
wide range of practices involved in cell line development, primary cell isolation and 
purification, and culturing conditions.  Using FTIR spectroscopy, we have identified the 
mineralized matrix produced by Runx2 overexpressing primary myoblasts as a carbonate 
containing, poorly crystalline apatite, similar to that produced by primary osteoblast 
cultures130.  Therefore, although the tissue-engineered constructs produced by the 
genetically engineered myoblasts are not necessarily identical in physical structure to 
native bone, they do replicate the physiological composition of bone tissue, and thus are a 
promising prospect for the healing of osseous defects. 
Several groups have shown that dynamic perfusion culture of cell-seeded 
scaffolds improves cellular viability, proliferation, and matrix mineralization throughout 
the scaffold137-139,141.  Additionally, architectural, mechanical, and biological properties of 
the scaffold play an equally important role as cell behavior in developing a successful 
tissue-engineered construct142,143.  We selected collagen-based scaffolds because this 
biological material has been used and characterized extensively for numerous medical 
applications including tissue engineering144,145.  Collagen scaffolds are biocompatible, 
biodegradable, and generally exhibit weak antigenicity in vivo.  In contrast to many 
polymeric scaffolds, collagen matrices are both osteoconductive and osteoinductive by 
playing a functional role in osteoblastic signaling and differentiation112,146-148. 
 Previous studies have demonstrated minimal mineralization by cells expressing 
Runx2 via a transient adenoviral vector56,78.  In contrast, the present results show 
significant levels of mineralization using sustained Runx2 expression from an integrated 
retroviral vector.  This suggests that sustained and/or threshold levels of Runx2 
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expression may be necessary for induction of matrix mineralization and conversion of 
non-osteogenic cells into a mineralizing osteoblastic phenotype.  It is not surprising that 
prolonged expression of an exogenous osteogenic factor is necessary to effect long-term 
functions such as matrix mineralization.  Furthermore, we have previously established 
cell-type dependence of Runx2-induced mineralization24, demonstrating the importance 
of cell source selection for bone tissue engineering applications.  Ongoing assessment of 
the osteogenic capacity of the skeletal myoblasts used in this study, including in vivo 
performance and direct comparison of Runx2- and BMP-based gene therapy strategies, is 
necessary to completely evaluate their utility for bone tissue engineering.  
This work is fundamentally different from BMP-based gene therapy strategies, 
which rely on both autocrine signaling by the genetically engineered cells and paracrine 
signaling by the secreted growth factor to neighboring endogenous cells, resulting in a 
hybrid bone tissue consisting of both native and implanted cells55,76,149.  Although these 
strategies have been very successful in stimulating bone formation in both ectopic and 
osseous environments51,55,57,150, they are still hampered by inadequate control of release 
kinetics, dosage, and potency.  In contrast, this transcription factor-based approach 
consists solely of an autocrine signal, resulting in an osteogenic response only by the 
genetically engineered cells.  Although this method does not take advantage of 
osteogenic induction of neighboring cells, it may avoid aberrant effects of unregulated 
growth factor secretion and provide a more controllable in vivo environment after ex vivo 
genetic modification.  Additionally, the ability of genetically engineered cells to 
mineralize and promote construct maturation in vitro, prior to implantation, may play an 
important role in the ultimate success of healing bone defects via tissue engineering.  In 
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fact, we have previously shown that in vitro development of mature mineralized scaffolds 
synergistically enhances ectopic mineralization in vivo77, suggesting that a cell source 
capable of in vitro mineralization may enhance the in vivo performance of these implants.  
In addition to Runx2- or BMP-based approaches, several groups have identified other 
mechanisms for osteoinduction.  Yang et al. have demonstrated a synergistic effect of 
combined Runx2 and BMP-2 adenoviral treatments on the C3H10T1/2 pluripotent cell 
line78, and exogenous expression of other osteogenic factors, such as LMP-1151  and 
Dlx5106, also enhances osteoblastic differentiation and matrix mineralization.   
In summary, this work demonstrates Runx2-genetically engineered primary 
skeletal myoblasts convert into an osteogenic lineage and mineralize collagen scaffolds in 
vitro.  These cells have the potential to overcome many cell sourcing obstacles of bone 
tissue engineering, including availability and preservation of function.  This strategy also 
establishes the potency of using genetic engineering techniques to target downstream 






IN VITRO AND IN VIVO OSTEOBLASTIC DIFFERENTIATION OF 
RUNX2- AND BMP-2-ENGINEERED SKELETAL MYOBLASTS* 
 
Introduction 
 Orthopedic substitutes are required for 2.2 million surgeries each year4. Bone 
tissue engineering has emerged as a promising approach to address the limitations of 
autogenous bone grafts, allografts, and synthetic implants4,35-37.  This strategy 
incorporates cells, a biodegradable scaffold, and bioactive factors into an implantable 
construct38,39.  However, a suitable autologous osteogenic cell source has been difficult to 
identify due to availability38, dedifferentiation following in vitro expansion47-49, and an 
age-related loss of phenotype50.  Therefore genetic engineering of readily accessible non-
osteoblastic cell types and progenitor cells, such as skeletal myoblasts, fibroblasts, and 
bone marrow-derived cells, has emerged as a promising method to induce osteoblastic 
differentiation and address these cell sourcing limitations.  The vast majority of these 
approaches utilize osteogenic growth factors, such as bone morphogenetic proteins 
(BMPs), or osteoblastic transcription factors, including Runx263,152.  However, the 
relative efficacy of these different approaches to induce osteoblastic differentiation 
remains unclear and is further complicated by varied delivery vehicles, cell types, and 
evaluation criteria. 
* Modified from 
C.A. Gersbach, R.E. Guldberg, and A.J. Garcia, In vitro and In vivo Osteoblastic Differentiation of BMP-




 BMP-2 is the most widely used growth factor to stimulate osteoblastic 
differentiation8.  Soluble BMP-2 protein acts in autocrine and paracrine fashions by 
binding extracellularly to transmembrane receptors and triggering an intracellular 
signaling cascade mediated by Smad proteins7.  Activated Smads translocate to the 
nucleus and upregulate the osteoblastic transcription factor Runx29.  Runx2 then 
coordinates osteoblastic gene expression, including osteocalcin, bone sialoprotein, 
osteopontin, and alkaline phosphatase20.  Runx2 expression is required for osteoblastic 
differentiation20 and endochondral ossification21.  BMP-2 signaling also functions via 
several Smad-independent pathways, including protein kinase C and D and MAPKs10.  
 Strategies that engineer cells to express a BMP-2 transgene have been successful 
in stimulating osteoblastic differentiation and ectopic and orthotopic bone formation in 
vivo63.  However, concerns regarding release kinetics, dosage, and target cell specificity 
of this secreted growth factor still remain152.  Furthermore, unregulated secretion of 
BMP-2 has been shown to stimulate tumor growth86,87,153 and bone overproduction88,89, 
where bone growth exceeds the defect site.  More recently, forced expression of Runx2, 
an intracellular effector, has been shown to induce osteoblastic differentiation20, matrix 
mineralization24, and in vivo bone formation78.  These results are consistent across 
pluripotent cell lines78 and primary cell types including fibroblasts56,83, skeletal 
myoblasts154, and bone marrow stromal cells77,79,82,155.   
These studies have established ex vivo gene therapy with BMP-2 and Runx2 as 
promising strategies for orthopedic regeneration.  However the relative potency and 
differential effects of these growth factor and transcription factor-based strategies in 
inducing osteoblastic differentiation are unclear.  In particular, the diverse use of transient 
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and sustained gene delivery vehicles, transformed and primary cell types, and methods 
for assessing osteoblastic differentiation causes comparisons between studies to be 
difficult.  Therefore, this study focuses on analyzing osteoblastic differentiation of a 
clinically relevant cell source engineered to express BMP-2 and/or Runx2 from a 
constitutive retroviral vector to obtain sustained expression of the transgene.  Primary 
skeletal myoblasts were used as a model non-osteoblastic autologous cell source 
available in large quantities by a muscle biopsy and compatible with in vitro expansion100 
and ex vivo gene therapy protocols62.  Skeletal myoblasts engineered to express BMP-2 
and/or Runx2 were assessed for osteoblastic differentiation in both monolayer and tissue-
engineered constructs in vitro, as well as in an ectopic implantation site in syngeneic 
mice in vivo.  Engineered cells were further characterized for their ability to induce 
osteoblastic differentiation through paracrine signaling.  
 
Materials and Methods 
Cell Culture 
 Primary skeletal myoblasts were isolated from the tibialis anterior muscles of 
adult male Balb/c mice and cultured in selective growth media (Ham’s F10, 20% fetal 
bovine serum, 5 ng/ml bFGF (Promega, Madison, WI), 100 U/ml penicillin G sodium, 
100 µg/ml streptomycin sulfate), yielding cultures that were greater than 99% myogenic 
by desmin staining100.  Cells were cultured on tissue culture plastic dishes coated with 
0.01% type I collagen (Vitrogen, Palo Alto, CA) in a humidified 5% CO2 atmosphere at 
37 ºC.  Cell culture media and antibiotics were obtained from Invitrogen (Carlsbad, CA), 
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fetal bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 
supplements and reagents were acquired from Sigma (St. Louis, MO). 
 
Retroviral Vectors 
 The pTJ66 retroviral vector156 and BMP-2 cDNA were generously provided by 
T.J. Murphy and Scott D. Boden, respectively.  The oligonucleotides 5’- 
AGGCCTAGACTGACAATTGGTATCGATGGCCTACA-3’ and 3’- 
ACATCCGGATCTGACTGTTAACCATAGCTACCGGA-5’ were annealed together to 
create an internal Mfe1 restriction site (underlined) with overhangs compatible with the 
Sfi1 cloning site of pTJ66.  The product was ligated into Sfi1-digested pTJ66 vector.  
Finally, the human BMP-2 cDNA was digested from the host vector with EcoRI 
restriction enzyme, ligated into the Mfe1 restriction site of pTJ66, and verified by 
sequencing the ligation points.  The pTJ66-Runx2 vector has been described previously24.   
 
Retroviral Transduction 
Retroviral stocks were produced by transient transfection of helper virus-free 
ΦNX amphotropic producer cells with plasmid DNA24.  Primary myoblasts were cultured 
up to 12 passages and plated on 0.01% collagen-coated tissue culture polystyrene at 2 x 
104 cells/cm2 24 h prior to retroviral transduction as described previously154.  Cells were 
transduced again 16 hrs later to increase transduction efficiency, and retroviral 
supernatant was replaced with differentiation media (αMEM, 10% fetal bovine serum, 
100 U/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid, 
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3 mM sodium β-glycerophosphate, and 10 nM dexamethasone).  Cell culture media was 
replaced every 3 days until terminal assay, unless noted otherwise.   
 
Osteogenic Differentiation 
 Quantitative RT-PCR (qRT-PCR), Western blotting, alkaline phosphatase 
biochemical activity, and von Kossa staining were performed as described previously154.  
Runx2 (Accession # NM_009820) primer sequences were 5’- 
GGCCTTCAAGGTTGTAGCCC -3’ (forward) and 5’- CCCGGCCATGACGGTA -3’ 
(reverse); BMP-2 (Accession # NM_001200) primer sequences were 5’- 
ATTGTGGCTCCCCCGG -3’ (forward) and 5’- TCAGCCAGAGGAAAAGGGC -3’ 
(reverse); VEGF-A (Accession # NM_009505) primers were 5’- 
CATCTTCAAGCCGTCCTGTGT -3’ (forward) and 5’- 
CAGGGCTTCATCGTTACAGCA -3’ (reverse).  Other primer sequences have been 
reported154.  Secreted BMP-2 protein levels were measured in bulk media samples using 
an ELISA kit according to the manufacturer’s instructions (R&D Systems, Minneapolis, 
MN).  Anti-phospho-Smad1/5/8 and anti-Smad1/5 were purchased from Chemicon 
(Temecula, CA) and Upstate Biotechnology (Charlottesville, VA), respectively.  Calcium 
content was determined by dissolving mineralized regions with 1 N acetic acid overnight.  
25 µl of appropriately diluted sample was added to 300 µl of arsenazo III-containing 
Calcium Reagent (Diagnostic Services Ltd., Oxford, CT).  The absorbance of the 
resulting samples was read at 650 nm and compared to a linear standard curve of CaCl2 in 




Scaffold Seeding and Analysis 
Fibrous collagen disks (5 mm x 1.5 mm, Kensey Nash, Exton, PA) were 
incubated overnight in 10% FBS in phosphate buffered saline (PBS).  At two days post-
transduction 250,000 cells in 10 µl of growth media were seeded onto each side of the 
disk in a non-tissue culture treated 24 well plate, for a total of 500,000 cells/construct.  
Four hours later, scaffolds were immersed in 2 ml of growth media.  After twenty-four 
hours, growth media was changed to 2 ml of differentiation media.  Media was replaced 
every three days until terminal assay.  FT-IR spectroscopy and DNA content were 
assessed as described previously157. 
 
Intramuscular Implantation  
 Scaffolds seeded with engineered or unmodified myoblasts were cultured for 1 or 
28 days in vitro and implanted into the hind limbs of syngeneic 6 week old 
immunocompetent male Balb/c mice (Jackson Labs, Bar Harbor, ME) in accordance with 
an IACUC-approved protocol.  A longitudinal 1 cm incision was made in the skin 
overlying the gastrocnemius muscle, and the muscle was exposed.  Scaffolds were 
inserted into the muscles of both legs through an atraumatic longitudinal split in the 
direction of the fibers. The muscle was closed over the implants (without suturing) and 
the skin closed with wound clips.  Twenty-eight days after implantation mice were 
euthanized by CO2 inhalation and lower legs were harvested, skinned, and fixed in 10% 






Mineralization of cell/scaffold constructs was quantified by high resolution X-ray 
micro-computed tomography (micro-CT) using a Scanco Medical VivaCT 40 imaging 
system (Bassersdorf, Switzerland).  Specimens were scanned at 21 µm voxel resolution 
and evaluated at a threshold corresponding to a linear attenuation of 1.92 cm-1, filter 
width of 1.2, and filter support of 2.0.  The reconstructed and thresholded 3-D images 
were evaluated using direct distance transformation methods to calculate mineralized 
matrix volume within each construct135. 
 
Histological Analysis 
 Formalin-fixed samples were decalcified with 5% formic acid prior to paraffin 
embedding for hematoxylin-eosin or Masson’s trichrome staining.  Sections (5 µm) were 
deparaffinized and stained as indicated. 
 
Data Analysis 
Data are reported as mean ± standard error of the mean (SEM), and statistical 
comparisons using SYSTAT 8.0 were based on an analysis of variance (ANOVA) and 




 Primary skeletal myoblasts were cultured up to 12 passages and transduced with 
empty vector, Runx2, and/or BMP-2 retroviral supernatant.  Combined Runx2 and BMP-
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2 treatment was performed by mixing equal volumes of retroviral supernatant.  The 
pTJ66 retroviral vector uses the promoter activity of the 5’ LTR for transgene expression, 
followed by an internal ribosomal entry site and a zeocin-resistance-enhanced green 
fluorescent protein (eGFP) fusion protein, allowing for noninvasive analysis of 
transduction efficiency24.  High levels of eGFP transgene expression were confirmed for 
all treatments by flow cytometry (Fig. 5.1A).  Transgene expression was further analyzed 
by qRT-PCR for Runx2 and BMP-2 mRNA levels (Fig. 5.1B).  Runx2 and BMP-2 
expression were significantly upregulated by treatment with Runx2 and BMP-2 
retrovirus, respectively.  Importantly, dilution of retroviral supernatant in the combined 
treatment did not affect transgene mRNA levels relative to undiluted virus stocks.  
Protein levels were assessed by Western blot for Runx2 (Fig. 5.1C) and ELISA of the 
bulk media for BMP-2 (Fig. 5.1D).  Neither Runx2 nor BMP-2 protein was detectable in 
control myoblasts.  Retroviral delivery of Runx2 significantly enhanced protein levels at 
3 and 7 days.  Lower levels of Runx2 protein were also detected in samples treated with 
BMP-2.  Runx2 overexpression alone did not induce BMP-2 expression.  However BMP-
2 protein in the bulk media was significantly reduced in the combined treatment relative 
to BMP-2 overexpression alone, despite equivalent BMP-2 mRNA levels.  Additionally, 
secreted amounts of BMP-2 protein decreased over time despite no significant changes in 
mRNA expression.  These observations may be explained by increased internalization or 
incorporation of soluble BMP-2 into the extracellular matrix assembled by Runx2- or 
BMP-2-engineered cells, or the upregulation of BMP-2-binding agonists, such as noggin.  
Nevertheless, these results confirm successful retroviral overexpression of substantial and 







Figure 5.1.  Retroviral expression of Runx2 and BMP-2 transgenes.  (A) Transduction 
was confirmed by flow cytometry.  (B)  Significant levels of Runx2 (p<1E-8) and BMP-2 
(p<9E-12) mRNA were detected by qRT-PCR in samples transduced with the respective 
virus (mean + SEM, n=3).  Elevated protein levels were detected by (C) Western blotting 
for Runx2 and (D) ELISA of the bulk media for BMP-2 (mean ± SEM, n=3, p<5E-12). * 








Osteoblastic Differentiation In Vitro 
 Gene expression was analyzed at 1, 3, and 7 days post-transduction for 
osteoblastic matrix proteins (osteocalcin and bone sialoprotein), transcription factors 
(Osterix and Dlx5), mineralization-associated enzymes (alkaline phosphatase), and 
angiogenic factors (VEGF-A) (Fig. 5.2).  Osteocalcin, bone sialoprotein, Osterix, and 
alkaline phosphatase were all upregulated by Runx2 or BMP-2 at 7 days.  Additionally, 
BMP-2 induced gene expression faster than Runx2 as evident by expression profiles at 1 
and 3 days. However, with the exception of bone sialoprotein, all genes showed similar 
levels in response to Runx2 and BMP-2 treatment after 7 days.  Bone sialoprotein was 
upregulated to a greater extent by BMP-2 relative to Runx2 treatment.  Interestingly, the 
combined treatment of Runx2 and BMP-2 resulted in synergistic effects (note logarithmic 
scale) on expression of osteocalcin, bone sialoprotein, Dlx5, and VEGF-A at later time 
points. 
 Functional osteoblastic differentiation was assessed by alkaline phosphatase 
biochemical activity and matrix mineralization in monolayer culture.  Alkaline 
phosphatase activity was undetectable in control myoblasts, but significantly induced in 
Runx2 and BMP-2 overexpressing cells (Fig. 5.3A).  At 14 days post-transduction 
enzyme activity was equivalent in cells with Runx2, BMP-2, and combined treatments.  
Matrix mineralization was assessed by calcium content (Fig. 5.3B) and von Kossa 
staining for phosphate deposits (Fig. 5.3C).  There were no mineralized regions detected 
in control samples.  Interestingly, Runx2 treated cells showed higher levels of 
mineralization than BMP-2 treated monolayer cultures for up to 8 weeks, despite similar 









Figure 5.2.  Runx2-and BMP-2-induced gene expression was assessed by qRT-PCR 
analysis of osteoblastic markers including osteocalcin (p<9E-10), bone sialoprotein 
(p<7E-12), Osterix (p<8E-12), Dlx5 (p<2E-6), alkaline phosphatase (p<9E-12), and 









Figure 5.3.  Osteoblastic differentiation of Runx2 and BMP-2 engineered myoblasts was 
analyzed by (A) alkaline phosphatase biochemical activity (p<7E-12, mean ± SEM, n=3), 
(B) calcium content (p<6E-12, mean ± SEM, n=3), and (C) von Kossa staining for 






Matrix Mineralization In Vivo 
Cells were seeded onto fibrous collagen disks to assess osteoblastic differentiation 
in a three-dimensional, tissue-engineered environment.  Mineralization on these scaffolds 
was assessed by micro-CT (Fig. 5.4A).  In contrast to two-dimensional monolayer 
cultures, BMP-2 expressing cells exhibited significantly higher levels of mineralization 
compared to Runx2 cells in the cell-scaffold construct.  The trends in calcium content of 
these constructs were similar to the levels of mineralization measured by micro-CT (data 
not shown).  Importantly, the increased amount of mineralization by BMP-2 cells 
correlated to higher cell numbers in the scaffold (Fig. 5.4B).  Constructs containing cells 
treated with both Runx2 and BMP-2 showed decreased cell numbers compared to BMP-2 
engineered cells, similar to cells expressing only Runx2.  The in vitro mineralization was 
confirmed to be a carbonate-containing biological hydroxyapatite by FT-IR spectroscopy, 
similar to that of cranial bone (Fig. 5.4C).  Constructs containing control myoblasts 
exhibited bands corresponding to a mineral-free extracellular matrix. 
 The cell-seeded collagen scaffolds were implanted intramuscularly into the hind 
limbs of immunocompetent syngeneic mice to evaluate the mineralization capacity of the 
genetically engineered cells in vivo.  Constructs were implanted 24 hrs after cell seeding 
or after 4 weeks of in vitro preculture, since we have previously shown enhanced 
mineralization in vivo after in vitro construct development77.  Mice were euthanized at 4 
weeks post-implantation and hind limbs were analyzed for ectopic mineralization by 
micro-CT and histology (Fig. 5.5).  Collagen/cell constructs that were implanted without 
pre-culture showed moderate levels of mineral deposits for empty vector or Runx2-







Figure 5.4.  Engineered cells were seeded onto fibrous collagen scaffolds and analyzed 
for mineralization by (A) micro-CT (p<1E-8, mean ± SEM, n=6) and (B) DNA content 
(p<8E-6, mean ± SEM, n=3).  * vs. empty vector, # vs. Runx2, § vs. BMP-2.  (C) In vitro 










for cell-free constructs and scaffolds containing non-engineered myoblasts.  Constructs 
with cells expressing BMP-2 alone or BMP-2 and Runx2 showed significantly greater 
amounts of ectopic mineralization.  In contrast, constructs which matured in vitro prior to 
implantation showed significant and equivalent amounts of mineral for Runx2, BMP-2, 
and dual treated cells relative to background levels with control cells.  Hematoxylin and 
eosin staining (Fig. 5.5B) showed greater cellularity in pre-cultured mineralized implants 
relative to empty vector controls, despite greater cell numbers on control scaffolds at 
implantation.  This result is likely due to minimal proliferation of differentiated myocytes 
in control samples, in vivo proliferation of implanted osteogenic cells, and/or recruitment 
of osteoprogenitors by cells engineered to express osteogenic factors.  Masson’s 
trichrome staining (Fig. 5.5C) also showed lower cell numbers in control samples (purple 
nuclei), as well as acellular residual collagen scaffold (blue and red).  Runx2, BMP-2, 
and dual treated samples showed significant matrix remodeling and/or deposition with 
collagen staining (blue) aligned and interwoven in highly cellularized regions, resembling 
early intramembranous bone formation.  Histological staining of implants consisting of 
scaffold only or scaffold with non-engineered cells were similar to empty vector samples 
for all analyses, suggesting no adverse response to retrovirally transduced cells. 
 
Paracrine Signaling 
 BMP-2 expressing cells are known to stimulate osteoblastic differentiation of 
neighboring cells through paracrine signaling by secreted BMP-2 growth factor55,76.  This 
effect is attributed to be greatly responsible for the considerable success of BMP-2-based 




Figure 5.5.  Cell-seeded collagen scaffolds were implanted intramuscularly in the hind 
limbs of immunocompetent syngeneic mice at 1 day post-seeding or after 28 days of in 
vitro pre-culture in differentiation media.  (A) Animals were euthanized at 4 weeks post-
implantation and formalin-fixed hind limbs were analyzed for ectopic mineralization by 
micro-CT (p<8E-7, mean ± SEM, n=6). * vs. empty vector, # vs. Runx2.  Images are 
representative of pre-cultured implants.  Pre-cultured samples were also assessed 
histologically by (B) hematoxylin and eosin and (C) Masson’s trichrome staining.  Scale 
bars indicate 50 µm. 
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ability to achieve targeted effects and may be responsible for abnormal bone 
formation88,89 and tumorigenesis86,87,153. It is unclear whether cells overexpressing Runx2, 
an intracellular effector, also transmit osteogenic signals through secretion of cytokines 
or growth factors.  Therefore we transduced cells with the indicated virus, exchanged 
media after two days, and harvested conditioned media at 4 days and every other day 
thereafter.  The conditioned media was immediately filtered through a 0.1 µm syringe 
filter and transferred to non-engineered myoblasts.  This process was repeated every 2 
days for 8 days, at which point both donor cells and cells receiving conditioned media 
(recipient cells) were harvested for analysis of osteogenic gene expression by qRT-PCR 
(Fig. 5.6A).  Donor cells, which were treated with the indicated retrovirus, showed 
similar expression profiles as in Figure 5.2.  Interestingly, conditioned media from any 
group did not effect the expression of osteocalcin, the most frequently characterized 
target of BMP-2 and Runx2.  However conditioned media from BMP-2-engineered cells 
induced both bone sialoprotein and Osterix expression in recipient cells.  Conditioned 
media from Runx2-engineered cells had no significant effects on any gene investigated.  
Furthermore, co-treatment with Runx2 and BMP-2 showed a decreased effect on bone 
sialoprotein and Osterix relative to BMP-2 alone, possibly due to the dilution of BMP-2 
protein detected in Figure 5.1D.  To further examine the possibility of BMP signaling in 
Runx2-treated cultures, levels of Smad activation were assessed by Western blot (Fig. 
5.6B).  Significant levels of Smad phosphorylation were detected in BMP-2-engineered 
cultures.  However, there was no detectable Smad activation in Runx2-overexpressing 








Figure 5.6.  Paracrine signaling by genetically engineered cells. (A) Conditioned media 
studies were performed to analyze the ability of engineered cells to transmit osteogenic 
signals via soluble growth factors or cytokines.  Donor myoblasts were engineered with 
the indicated retrovirus and differentiation media was exchanged every other day.  
Starting at 4 days post-transduction, media harvested from donor cells was filtered and 
added to non-engineered myoblasts (recipient cells) for a total of 8 days.  Both donor 
cells and recipient cells were analyzed by qRT-PCR for osteocalcin (p<4E-9), bone 
sialoprotein (p<8E-12), and Osterix (p<2E-9) gene expression (mean ± SEM, n=3).  * vs. 
empty vector, # vs. Runx2, § vs. BMP-2.  (B) Phosphorylation of Smad signaling 
molecules was analyzed by Western blot.  The presence of phosphorylated Smads in 
BMP-2-engineered cells confirmed activation of BMP signaling pathways.  There was no 
Smad phosphorylation detected in Runx2-treated samples, demonstrating osteoblastic 







to BMP-2-secreting cells, do not utilize paracrine signaling by soluble factors in 
stimulating osteoblastic differentiation.  
 
Discussion 
 Genetic engineering of non-osteoblastic cells with osteogenic factors has emerged 
as a promising strategy to address cell sourcing limitations associated with bone tissue 
engineering.  However, the relative efficacy of these different approaches to induce 
osteoblastic differentiation remains unclear and is further complicated by varied delivery 
vehicles, cell types, and evaluation criteria.  The present study provides a direct and 
quantitative comparison between transcription factor- and growth factor-based strategies 
to induce osteoblastic differentiation in vitro and in vivo.  We used retroviral delivery to 
primary skeletal myoblasts inorder to compare sustained expression of Runx2 and BMP-
2 transgenes in a clinically relevant autologous cell source61.  This work supports 
previous studies which indicate that BMP-2 overexpression may be a more potent 
osteoinductive strategy56,78.  However, these results also suggest that Runx2 
overexpression can be an equally effective approach under the appropriate conditions or 
when measured at longer time points.   
This study highlights the need for rigorous evaluation of osteoinductive strategies 
in multiple settings to define an appropriate method to achieve a desired therapeutic 
outcome.  Runx2-overexpressing cells generated greater mineralization in confluent 
monolayer cultures relative to BMP-2-treated cells.  This is consistent with previous 
results comparing Runx2 overexpression with treatment of recombinant BMP-2 
protein154.  However BMP-2 engineered cells showed significantly greater levels of 
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mineralization in three-dimensional collagen scaffolds, correlating with greater cell 
numbers.  Runx2 and BMP-2 are both known to mediate proliferation, cell cycle 
progression, and apoptosis of osteoblastic cells158,159.  The greater numbers of BMP-2-
expressing cells on cultured collagen scaffolds could be explained by Runx2-mediated 
inhibition of proliferation158, BMP-2-mediated suppression of apoptosis159, or differences 
in osteoblastic activity in two- and three-dimensional culture160-162.  These results 
underscore the necessity for measuring several parameters of cell activity in multiple 
environments when assessing cell sources for gene therapy strategies in orthopedic 
regeneration. 
Yang et al. demonstrated a synergistic effect on osteogenesis with dual treatment 
of BMP-2 and Runx2 adenoviral vectors in a multipotent mesenchymal cell line78.  
Although we show synergistic effects on osteoblastic gene expression, this effect was not 
propagated to downstream cellular effects including enzyme activity and mineralization.  
The inconsistencies between these studies may be the result of differences relating to 
transient expression in a multipotent cell line versus sustained transgene expression in a 
lineage-committed primary cell type.  We also show diminished detection of secreted 
BMP-2 in Runx2 co-expressing cultures (Fig. 5.1D) without a loss of osteoblastic 
activity.  This may be the result of enhanced cellular uptake or BMP-2 incorporation in 
the extracellular matrix.  Further investigation is necessary to determine whether these 
mechanisms contribute to the observed synergy in dually-treated cells.  Additionally, we 
did not observe the development of osteocytes, cartilage, or marrow cavities as reported 
for Runx2- and BMP-2-engineered cell lines implanted in ectopic sites in 
immunodeficient mice78.  Previous studies suggest that this may be the result of using 
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primary cells and immunocompetent mice in the present work, and longer implantation 
times may be necessary for the development of more complex tissues69.  
Paracrine signaling by BMP-2-expressing cells plays a central role in stimulating 
osteogenesis76,112.  This effect can be advantageous for obtaining an adequate degree of 
osteoblastic differentiation and mineralization.  However, the unregulated secretion of 
potent signaling molecules limits target cell specificity and risks tumorigenesis86,87,153 or 
abnormal bone formation88,89.  Choi et al. have described a mechanism by which Runx2 
induces BMP-2 expression163, suggesting that Runx2-overexpressing cells may stimulate 
osteoblastic differentiation via paracrine signaling of secreted factors.  Additionally, a 
recent report suggests that BMP signaling is required for Runx2-stimulated osteoblastic 
differentiation164.  However, we did not detect secretion of BMP-2 or BMP-4 into the 
surrounding media by Runx2-engineered cells.  Furthermore, there were no detectable 
levels of Smad activation in these cells, nor was there any effect of conditioned media 
from Runx2-engineered cells on osteogenic gene expression.   These results suggest that 
BMP signaling was not involved in Runx2-stimulated osteoblastic differentiation of 
primary skeletal myoblasts in this system.  The discrepancies between these studies may 
be the result of cell-type dependent effects in stimulating osteoblastic differentiation24.  In 
fact, although Runx2 binding sites have been identified in the promoters of the human 
BMP-2 and BMP-4 genes, deletion of these sites did not alter promoter activity in 
osteoblastic cells165. 
In addition to BMP-2 and the Runx2 transcription factor, there are several other 
gene therapy-based strategies under investigation for orthopedic regeneration.  Promising 
results have been achieved by focusing on other members of the BMP family55,166, VEGF 
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and RANK-L72, constitutively active BMP receptors73, and LIM-mineralization protein81.  
Other studies have demonstrated synergistic effects by incorporating multiple 
transgenes70,78 and transgenes supplemented with glucocorticoids83 or 
immunosuppressive agents84,85.  Additionally, the limitations of uncontrolled growth 
factor secretion and constitutive transgene expression are also being addressed with 
inducible expression systems65,71,88 and coexpression of regulatory factors89.  
This study emphasizes the complexity of ex vivo gene therapy as an integrated 
relationship of cell activity and differentiation state, construct maturation, and paracrine 
signaling of osteogenic cells.  Our results indicate that sustained BMP-2 expression in 
skeletal myoblasts is a more potent strategy for osteoinduction compared to delivery of 
the Runx2 transcription factor.  However, we also identified conditions in which Runx2 
is equally effective as BMP-2 in stimulating osteoblastic differentiation and matrix 
mineralization.  Furthermore, Runx2-based strategies may avoid complications arising 
from uncontrolled signaling of secreted factors.  Collectively, these results underscore the 
necessity for thorough evaluation of genetically engineered cells to identify the 
appropriate system for specific clinical needs.  This work is significant to evaluating 
these systems and defining a successful strategy for integrating gene medicine and 









 Cell-based therapies have emerged as a promising approach for orthopedic 
regeneration.38  However, autologous osteoblastic cell sources are limited by 
availability38, dedifferentiation following in vitro culture47-49, and an age-related decrease 
in osteogenic capacity.50  To address these limitations, genetic engineering has become a 
central component of many regenerative medicine strategies.  Forced expression of 
differentiation factors is commonly used to enhance cell phenotype or modulate cell 
function to achieve a therapeutic goal.  In particular, cell-based approaches to bone tissue 
engineering often utilize ex vivo gene therapy techniques to induce osteogenesis in non-
osteoblastic cell types, including myoblasts57,157, fibroblasts55,56, and pluripotent 
progenitor cells.51-54  These strategies focus on the constitutive overexpression of 
osteogenic growth and differentiation factors, such as bone morphogenetic proteins 
(BMPs)68,75,166,167 or osteoblastic transcription factors, including Runx2.67,77,79,155,157  
These approaches have been successful in stimulating osteoblastic differentiation and in 
vivo bone formation.63  However, unregulated overexpression of these proteins risks 
aberrant effects of uncontrolled cell signaling, including tumorigenesis86,87 and abnormal 
bone formation.88,89  
The use of inducible expression systems is a promising method for controlling the 
* Modified from 
C.A. Gersbach, J.M. Le Doux, R.E. Guldberg, and A.J. Garcia, Inducible Regulation of Runx2-Stimulated 
Osteogenesis.  Gene Therapy, 2006.  13(11):873-882.  
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behavior of genetically engineered cells.74  These systems typically drive transgene 
expression from inducible promoters regulated by non-mammalian transcription factors.  
The activity of these transcription factors is controlled by exogenous chemical agents 
which permit (“on” state) or repress (“off” state) transgene expression.  In principle, an ex 
vivo inducible gene therapy strategy entails implanting engineered cells into a bone defect 
site and maintaining transgene expression in the “on” condition.  When adequate healing 
has occurred, cells are moved to the “off” condition to prevent any adverse effects of 
prolonged transgene overexpression.  Additionally, incorporating regulation into these 
systems allows analysis of unique patterns of transgene expression, including varying 
duration and magnitude of expression, cycling expression over time, and coordinating the 
sequential presence of multiple exogenously expressed genes.   
The most widely characterized of these systems is the tetracycline inducible 
expression system, first described by Gossen and Bujard.90  The original system utilizes 
the tetracycline-controlled transactivator (tTA), a fusion protein of the E. coli tet 
repressor and the activating domain of virion protein 16 of the herpes simplex virus.  In 
the absence of tetracycline, tTA binds the tet operon and activates transcription of a 
downstream gene of interest.  However, in the presence of subtoxic levels of tetracycline, 
the antibiotic binds to tTA, blocking binding of the tet operon and subsequent 
transactivation in a dose-dependent manner.  This “tet-off” version was later modified to 
a “tet-on” system where transactivation increases with tetracycline concentration.91  
Despite the greater clinical relevance of the tet-on derivative, the tet-off system is widely 
reported as having a greater degree of inducibility, including lower expression levels in 
the “off” state and higher expression levels in the “on” state.92  In addition, this system is 
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compatible in vitro by adding tetracycline to the cell culture media and in vivo by 
delivering aTc via the drinking water.    
Both tetracycline-based systems have been used to express BMP transgenes for 
bone regeneration.65,71,88  BMP-2, the most widely used BMP for osteoinduction, is a 
secreted growth factor that acts via autocrine and paracrine mechanisms by binding to the 
extracellular domain of a transmembrance receptor that activates the intracellular Smad 
signaling pathway.7  Activated Smads translocate to the nucleus, upregulating and 
cooperating with the osteoblast-specific transcription factor Runx2 to induce osteoblastic 
gene expression.11  Runx2 is essential for osteoblast differentiation20 and endochondral 
ossification.21   
Although genetic engineering with BMPs has successfully stimulated 
osteogenesis in many models, concerns over dosage, release kinetics, and target 
specificity still remain.152  Forced expression of Runx2, an intracellular effector, 
enhances the differentiation of an osteogenic cell source24,82 and stimulates 
transdifferentiation of primary skeletal myoblasts into an osteoblastic phenotype.154  
Runx2 overexpression has also been recently advocated as a method for maintaining and 
enhancing an osteoblastic phenotype for bone regeneration77,79,155,157 and may overcome 
potential limitations of genetic engineering with secreted growth factors.  However, the 
ability to direct osteoblastic differentiation with an inducible Runx2 expression system 
has not been demonstrated. 
To generate a system for efficient and regulated transgene expression, we utilized 
a retroviral tet-off expression system156 to modulate Runx2 expression.  Primary skeletal 
myoblasts were used as a clinically relevant autologous cell source that is responsive to 
 
 91
Runx2 overexpression.154,157  We demonstrate that the osteogenic effect of Runx2 
overexpression in primary skeletal myoblasts can be regulated by a tetracycline-
responsive expression system both in vitro and in vivo.  The conversion of Runx2-
engineered skeletal myoblasts into an osteoblastic phenotype is inducible, repressible, 
recoverable after suppression, and dose-dependent with tetracycline concentration. This 
work is significant in developing controlled, effective gene therapy methods for 
regenerative medicine and represents a novel strategy for investigating the effects of 
temporal modulation and magnitude of expression levels on osteoblastic differentiation.  
 
Materials and Methods 
Cell Culture 
 Primary skeletal myoblasts were isolated from the tibialis anterior muscles of 
adult male Balb/c mice and cultured in selective growth media (Ham’s F10, 20% fetal 
bovine serum, 5 ng/ml bFGF (Promega, Madison, WI), 100 U/ml penicillin G sodium, 
100 µg/ml streptomycin sulfate), yielding cultures that were greater than 99% myogenic 
by desmin staining.100  Cells were cultured on tissue culture plastic dishes coated with 
0.01% type I collagen (Vitrogen, Palo Alto, CA) in a humidified 5% CO2 atmosphere at 
37 ºC.  Cell culture media and antibiotics were obtained from Invitrogen (Carlsbad, CA), 
fetal bovine serum was purchased from Hyclone (Logan, UT), and all other cell culture 







 Retroviral plasmids pTJ66, pKA23, and pXF40 were generously provided by T.J. 
Murphy.156  The tTA gene was digested from the pKA23 plasmid with Sfi1 restriction 
enzyme and ligated into the Sfi1 cloning site of the constitutive retroviral expression 
vector pTJ66 (Fig. 6.1A).  The pTJ66-tTA retroviral vector uses the promoter activity of 
the 5’ long terminal repeat (LTR) to express a single bicistronic mRNA encoding tTA, 
followed by an internal ribosomal entry site (IRES) and a zeocin resistance-enhanced 
green fluorescent protein fusion protein (Zeo(r):eGFP), allowing for noninvasive analysis 
of transduction efficiency and antibiotic selection for transduced cells (Fig. 6.1B). 
 Two Sfi1 restriction sites were inserted into the multiple cloning site of pXF40, 
the retroviral tetracycline-inducible expression vector.  The oligonucleotides 5’-
CGCGTTGATCAGGCCTTGTAGGCCTAGGGATCCGTAGGCCTACAAGGCCTTC
GAAATGCA-3’ and 5’-TTTCGAAGGCCAAGTAGGCCTACGGATCCCTAGGCCTA 
CAAGGCCTGATCAA-3’ (Sfi1 sequences underlined) were annealed together, creating 
Nsi1- and Mlu1-compatible overhangs at each end.  This product was then ligated into a 
linearized pXF40 vector which had been digested with both Nsi1 and Mlu1.  Finally, the 
Runx2 gene was digested from the TJ66 vector with Sfi1 enzyme, and ligated into a Sfi1-
digested pXF40 vector.  The pXF40-Runx2 vector transcribes the Runx2 gene from the 
tetracycline-inducible promoter, which consists of seven adjacent copies of the tet operon 
(tetO).  This vector also constitutively expresses the neomycin resistance gene (Neo(r)) 
by the 5’ LTR promoter, allowing for selective purification of transduced cells.  All 





Retroviral stocks were produced by transient transfection of helper virus-free 
ΦNX amphotropic producer cells with plasmid DNA as previously described.24  For 
production of pXF40-Runx2 retrovirus, cells were maintained in 1 µg/ml 
anhydrotetracycline (aTc), as inactivating conditions enhance retroviral titer of 
tetracycline inducible vectors.   
  Primary myoblasts were cultured up to 12 passages and plated on 0.01% collagen-
coated tissue culture polystyrene at 2 x 104 cells/cm2 24 h prior to retroviral 
transduction.62  Cells were transduced with 0.2 ml/cm2 of equal parts pTJ66-tTA and 
pXF40-Runx2 retroviral supernatant supplemented with 4 µg/ml hexadimethrine bromide 
(Polybrene), 5 ng/ml bFGF, and 10% fetal bovine serum, and centrifuged at 2500 rpm 
(1200 g) for 30 min in a Beckman model GS-6R centrifuge with a swinging bucket rotor.  
Retroviral supernatant was replaced with growth media and 1 µg/ml aTc.  Forty-eight 
hours following transduction, growth media was supplemented with 1 µg/ml aTc, 500 
ng/ml G418 sulfate, and 500 ng/ml zeocin.  Following two weeks of culture in selective 
growth media in the “off” condition, cells were plated at 50,000 cells/cm2 in 0.01% 
collagen-coated 6-well plates for end-point assays.  Twenty-four hours after plating, cells 
were washed twice with PBS to remove residual aTc, and growth media was replaced 
with differentiation media (αMEM, 10% fetal bovine serum, 100 U/ml penicillin G 
sodium, 100 µg/ml streptomycin sulfate, 50 µg/ml L-ascorbic acid, 3 mM sodium β-
glycerophosphate, and 10 nM dexamethasone) supplemented with the indicated 
concentration of aTc.  Cell culture media was replaced every 3 days until terminal assay, 





 Quantitative RT-PCR (qRT-PCR), Western blotting, alkaline phosphatase 
biochemical activity, and von Kossa staining were performed as described previously.154  
Calcium content was determined by dissolving mineralized regions with 1 N acetic acid 
overnight.  25 µl of appropriately diluted sample was added to 300 µl of arsenazo III-
containing Calcium Reagent (Diagnostic Services Ltd., Oxford, CT).  The absorbance of 
the resulting samples was read at 650 nm and compared to a linear standard curve of 
CaCl2 in 1 N acetic acid.   
 
Scaffold Seeding and Analysis 
Fibrous collagen disks (5 mm x 1.5 mm, Kensey Nash, Exton, PA) were 
incubated overnight in 10% FBS in phosphate buffered saline (PBS).  250,000 cells in 10 
µl of growth media were seeded onto each side of the disk in a non-tissue culture treated 
24 well plate, for a total of 500,000 cells/construct.  Four hours later, scaffolds were 
immersed in 2 ml of growth media.  After twenty-four hours, growth media was changed 
to 2 ml of differentiation media with or without 100 ng/ml aTc.  Media was replaced 
every three days until terminal assay.  FT-IR spectroscopy and DNA content were 
assessed as described previously.157 
 
Intramuscular Implantation  
 Scaffolds seeded with engineered or unmodified myoblasts were cultured for 28 
days in vitro and implanted into the hind limbs and 6 week old immunocompetent male 
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Balb/c mice (Jackson Labs, Bar Harbor, ME) in accordance with an IACUC-approved 
protocol.  A longitudinal 1 cm incision was made in the skin overlying the gastrocnemius 
muscle, and the muscle was exposed.  Scaffolds were inserted into the muscles of both 
legs through an atraumatic longitudinal split in the direction of the fibers. The muscle 
was closed over the implants (without suturing) and the skin closed with wound clips.  
Drinking water containing 5% sucrose with or without 1 mg/ml aTc was replaced every 3 
days.  28 days after implantation mice were euthanized by CO2 inhalation and lower legs 
were harvested, skinned, and fixed in 10% neutral buffered formalin.    
 
Micro-Computed Tomography 
Mineralization of 3-D scaffolds was quantified by high resolution X-ray micro-
computed tomography (micro-CT) using a Scanco Medical VivaCT 40 imaging system 
(Bassersdorf, Switzerland).  Specimens were scanned at 21 µm voxel resolution and 
evaluated at a threshold corresponding to a linear attenuation of 1.92 cm-1, filter width of 
1.2, and filter support of 2.0.  The reconstructed and thresholded 3-D images were 
evaluated using direct distance transformation methods to calculate mineralized matrix 
volume within each construct.135 
 
Histological Analysis 
 Formalin-fixed samples were paraffin embedded for von Kossa-nuclear fast red or 
hematoxylin-eosin staining, or decalcified with 5% formic acid prior to embedding for 





Data are reported as mean ± standard error of the mean (SEM), and statistical 
comparisons using SYSTAT 8.0 were based on an analysis of variance (ANOVA) and 
Tukey’s test for pairwise comparisons, with a p-value < 0.05 considered significant.  
Dose response curves were fitted to a 4-parameter sigmoid, and R-squared values 
calculated with SigmaPlot 2001. 
 
Results 
Tetracycline-inducible Runx2 expression system  
Primary skeletal myoblasts from mature male mice were transduced 
simultaneously with pTJ66-tTA and pXF40-Runx2 retroviral supernatants (Fig. 6.1A) in 
the presence of anhydrotetracycline (aTc).  aTc is a tetracycline derivative that has higher 
affinity for tTA and lower antibiotic activity than tetracycline.168  Cells were passaged in 
growth media supplemented with 100 ng/ml aTc, 500 µg/ml zeocin, and 500 µg/ml G418 
sulfate to select for cells which had integrated both retroviral vectors.  After 2 weeks, 
selective antibiotics were removed from the media and cells were plated for experiments 
in growth media with 100 ng/ml aTc.  Flow cytometry indicated that this cell population 
strongly expressed eGFP from the pTJ66-tTA vector (Fig. 6.1B), demonstrating 
successful retroviral transduction and integration, antibiotic selection, and transgene 
expression.  Twenty-four hours after plating, growth media was replaced with 
differentiation media with the indicated concentration of aTc.  Quantitative RT-PCR 
(qRT-PCR) and Western blotting at 7 days demonstrated high levels of Runx2 expression 
in the absence of aTc and a dose-dependent decrease in Runx2 expression with aTc 
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concentration (Fig. 6.1C-D).  Although the profile of Runx2 mRNA expression is 
accurately represented in Figure 6.1C, the magnitude of change in Runx2 expression is 
possibly skewed by the detection of antisense Runx2 mRNA transcribed by the 5’ LTR 
promoter of pXF40-Runx2.   Therefore the degree of inducibility with this system is 
likely much greater than the 3-fold increase observed by qRT-PCR and is more 
accurately represented by protein levels displayed in Figure 6.1D.  Importantly, no Runx2 
protein was detected at high levels of aTc, suggesting that Runx2 expression can be 
adequately suppressed in the “off” condition.  These results demonstrate a functioning 
aTc-inducible Runx2 expression system in primary skeletal myoblasts.   
 
Osteogenic and myogenic gene expression  
Runx2 is a known regulator of many osteoblast-specific genes20 and repressor of 
myogenesis.154  Therefore we assessed the effects of inducible Runx2 expression on 
osteoblastic and myogenic gene expression by qRT-PCR after 7 days in the indicated aTc 
concentration (Fig. 6.2).  Expression of the osteoblastic markers osteocalcin, bone 
sialoprotein, osteopontin, and Osterix was dependent on aTc concentration and correlated 
strongly with Runx2 expression.  These markers were repressed to levels equivalent to 
expression by unmodified myoblasts by 10 ng/ml aTc, demonstrating rigorous control of 
Runx2 expression and transactivation.  Conversely, myogenin and troponin T, markers 
associated with myoblastic differentiation, were regulated in an opposite fashion by aTc, 
indicating Runx2-dependent suppression of myogenesis.  Interestingly, these results 
suggest that the phenotype of these cells can be controlled by aTc concentration.  In the 










Figure 6.1.  Tetracycline-inducible Runx2 expression system.  (A) Retroviral vectors.  
The tetracycline-controlled transactivator (tTA) was constitutively expressed by pTJ66-
tTA.  Runx2 expression was controlled via the tet operon of pXF40-Runx2.  (B) 
Detection of eGFP expression by flow cytometry confirmed retroviral transduction and 
antibiotic selection of primary skeletal myoblasts.  (C) Runx2 mRNA (mean ± SEM, 
n=3) and (D) protein levels are dependent on aTc concentration after 7 days in 
differentiation media, demonstrating a functional aTc-inducible Runx2 expression system 
in primary skeletal myoblasts.  The magnitude of Runx2 mRNA levels (C) is skewed by 
detection of Runx2 antisense mRNA transcribed by the 5’ LTR promoter. However, 
Western blotting (D) confirmed undetectable levels of Runx2 protein at ≥10 ng/ml aTc, 













Figure 6.2.  Inducible regulation of osteogenic and myogenic gene expression (mean ± 
SEM, n=3).  Osteoblastic markers osteocalcin, bone sialoprotein, osteopontin, and 
Osterix were expressed at high levels in the absence of aTc and showed a dose-dependent 
decrease to background levels with aTc concentration.  Conversely, myogenin and 
troponin T, markers of myogenic differentiation, increased with aTc concentration, 
indicating Runx2-dependent suppression of myogenesis.  These results demonstrate cells 
maintaining a myogenic phenotype in the presence of ≥10 ng/ml aTc and an osteoblastic 
phenotype in the absence of aTc.  Dotted line represents expression levels in unmodified 







However, in the absence of aTc, Runx2 expression results in the upregulation of 
osteoblastic markers and suppression of myogenesis. 
  
In vitro mineralization 
The functional effects of inducible gene expression on osteoblastic differentiation 
were examined by alkaline phosphatase biochemical activity at 14 days and matrix 
mineralization at 28 days via calcium content analysis and von Kossa staining for 
phosphate deposits (Fig. 6.3).  All of these assays followed a similar aTc-dependent 
pattern as Runx2 and osteoblastic gene expression, with high levels of mineralization in 
the absence of aTc (high Runx2 levels) and undetectable amounts of alkaline phosphatase 
activity, calcium and phosphate in as low as 1 ng/ml aTc (low Runx2 levels).  
Additionally, cultures with ≥10 ng/ml aTc consisted of large multinucleated myotubes 
demonstrating myogenic differentiation, whereas cultures without aTc contained 
mononucleated cells with cobblestone morphology, typical of the osteoblast phenotype.  
These results suggest that myoblasts engineered with an inducible Runx2 expression 
system transdifferentiate into an osteoblastic phenotype in the absence of aTc, similar to 
myoblasts engineered to constitutively express a Runx2 transgene.154 
  
Temporal regulation of osteoblastic differentiation 
One major advantage of inducible expression systems is the ability to 
exogenously manipulate transgene expression over time.  To investigate the effects of 
temporal modulation of Runx2 expression, cells were cultured in differentiation media 







Figure 6.3.  Inducible regulation of osteoblast differentiation.  (A) Alkaline phosphatase 
biochemical activity and (B) calcium content decreased in a dose-dependent manner with 
aTc concentration (mean ± SEM, n=3), correlating with Runx2 and osteoblastic gene 
expression.  Dotted line represents levels in unmodified primary skeletal myoblasts.   (C) 
von Kossa staining showed significant phosphate deposits in cultures without aTc, 
whereas cultures with 100 ng/ml aTc showed no positive staining.  These results 





media for another 8 days.  Samples were taken every 2 days to measure Runx2 protein 
levels (Fig. 6.4A) and osteocalcin gene expression (Fig. 6.4B).  Both Runx2 and 
osteocalcin levels increased over 8 days in the absence of aTc, but rapidly returned to 
background levels after aTc was added back to cultures.  There was a short lag time (~2 
days) between reaching maximum levels of Runx2 protein and osteocalcin mRNA.  
Notably, myoblasts that were cultured in differentiation media with 100 ng/ml aTc for 8 
days and allowed to undergo myogenic differentiation also upregulated Runx2 and 
osteocalcin upon induction with similar kinetics as cells that upregulated Runx2 directly 
after removal of growth media.  This suggests that both undifferentiated myoblasts and 
cells in the later stages of terminal myogenic differentiation convert to an osteoblastic 
phenotype in response to forced Runx2 expression with a similar manner and magnitude.  
These results indicate that the cellular response to Runx2 activity is not affected by the 
differentiation state of primary skeletal myoblasts.  This hypothesis was corroborated by 
assessing mineralization in cells cultured with or without 100 ng/ml aTc for 28 and 56 
days (Fig. 6.4C).  Cells without aTc incorporated significant amounts of calcium into 
their matrix, whereas cultures in the presence of aTc did not exhibit detectable levels of 
calcium incorporation.  However, when aTc was added to cultures at 28 days, the rate of 
calcium incorporation was significantly decreased relative to cells without aTc.  The 
increase in calcium levels despite aTc supplementation may be the result of nucleation of 
mineral deposits already present and/or continued mineralization during the degradation 
of Runx2-dependent osteoblastic protein and mRNA molecules.  Additionally, myoblasts 
cultured in differentiation media with aTc for 28 days incorporated higher (p<1E-5) 










Figure 6.4.  Temporal regulation of Runx2-stimulated osteoblastic differentiation.  Cells 
were cultured with or without 100 ng/ml aTc for 8 days before aTc was removed or 
added back to the media.  Cultures were harvested every 2 days to assess (A) Runx2 
protein by Western blot or (B) osteocalcin mRNA by qRT-PCR (mean ± SEM, n=3, 
ANOVA p<9E-12).  Both Runx2 and osteocalcin increased over 8 days without aTc and 
were subsequently suppressed to background levels after aTc was added back to the 
culture media.   Additionally, myoblasts cultured in differentiation media with aTc for 8 
days upregulated Runx2 and osteocalcin to similar levels as cultures in which aTc was 
removed at the same time as growth media.  (C) Mineralization by cells cultured without 
aTc for 28 days was significantly decreased by adding aTc back to media as measured by 
calcium content at 56 days (mean ± SEM, n=3, ANOVA p<7E-12).  100 ng/ml aTc 
repressed mineralization in cells for 56 days, but calcium content was enhanced in the 
same cultures when aTc was removed at 28 days.  
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upregulated Runx2 before undergoing long-term myogenic differentiation.  This result 
can be explained by the greater cell number at 28 days of culture relative to cultures that 
upregulated Runx2 beginning 1 day after seeding.  Collectively, these results demonstrate 
a functioning inducible Runx2 expression system which regulates the conversion of 
primary skeletal myoblasts into an osteoblastic phenotype. 
  
In vivo mineralization 
Cells were seeded onto fibrous collagen scaffolds to evaluate this inducible 
Runx2 expression system in the context of a three-dimensional tissue-engineered 
environment.  DNA content gradually decreased over 56 days of in vitro culture (Fig. 
6.5A), potentially due to loss of nonadherent cells and cell death in the construct interior 
due to nutrient transport limitations associated with static culture.139,157  This effect is 
enhanced in constructs without aTc at 56 days, likely due to the mineral deposits that 
occur predominantly at the construct periphery.  Micro-computed tomography (micro-
CT) was used to detect mineralized regions at 28 and 56 days (Fig. 6.5B).  Consistent 
with the mineralization analyses of monolayer cultures, constructs cultured in 100 ng/ml 
aTc did not develop any mineralized regions.  In contrast, constructs cultured without aTc 
developed punctate mineralized regions by 56 days.  Fourier transform infrared (FT-IR) 
spectroscopy was used to determine the chemical composition of this mineral phase (Fig. 
6.5C).  Spectra of constructs cultured without aTc exhibited peaks representative of a 
carbonate-containing, biological hydroxyapatite similar to that of cranial bone.130  Spectra 
of samples cultured with aTc contained only amide peaks, which are representative of an 




Figure 6.5.  In vitro mineralization of collagen scaffolds seeded with Runx2-engineered 
myoblasts.  Cell-seeded scaffolds were cultured for the indicated time in vitro.  (A) DNA 
content decreased over time (mean ± SEM, n=3, ANOVA p<7E-12).  (B) Mineralized 
regions were detectable by micro-CT at 56 days in samples without aTc (mean ± SEM, 
n=6, ANOVA p<3E-4, * vs. day 56 + aTc p<5E-3).  Images are representative of 56 day 
constructs.  (C) FT-IR spectroscopy confirmed that mineral deposits were a carbonate-
containing biological hydroxyapatite, similar in chemical composition to cranial bone.  
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The ultimate application of a tetracycline-inducible Runx2 expression system is to 
control bone formation in vivo.  Therefore we implanted constructs consisting of collagen 
scaffolds and Runx2-engineered myoblasts in the hind limb muscles of 
immunocompetent syngeneic mice for 28 days.  Constructs were cultured for 28 days in 
vitro with or without 100 ng/ml aTc prior to implantation to allow for maturation of the 
cell-scaffold composite.77  Drinking water was supplemented with 5% sucrose and 1 
mg/ml aTc where indicated.  Explants were analyzed by micro-CT and histochemical 
staining for mineralization and cellular morphology and distribution.  Micro-CT showed 
distinct mineralization of constructs explanted from mice fed with sucrose only (Fig. 
6.6A).   These mineralized regions attenuated x-rays similarly to native trabecular bone in 
the femur and tibia.  Explants from mice which were fed aTc displayed no mineralization 
above background, similar to control constructs seeded with untransduced myoblasts.  
von Kossa staining for phosphate deposits showed mineralized regions dispersed 
throughout the implant without aTc, whereas no positive staining was present in 
constructs with aTc (Fig. 6.6B).  These results show that in vivo mineralization by these 
engineered cells can be exogenously regulated through aTc supplementation of the 
drinking water.  Hematoxylin and eosin staining showed significantly higher cellularity in 
constructs without aTc (Fig. 6.6C), despite equivalent cell numbers at implantation (Fig. 
6.5A).  Also, a considerable amount of collagen scaffold (pink regions) was still present 
in samples with aTc after 28 days of implantation.  This finding suggests both a higher 
degree of scaffold/matrix remodeling as well as cell proliferation and/or recruitment in 
constructs containing Runx2-expressing cells.   Masson’s trichrome staining of collagen 
(blue) displayed large amounts of acellular residual scaffold in implants with aTc (Fig. 
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6.6D).  However, in addition to acellular scaffold material, implants without aTc 
contained significant collagen staining aligned and interwoven in highly cellularized 
regions, indicating matrix remodeling and/or deposition in a manner resembling early 
intramembranous bone formation.  Histological staining of implants seeded with 
unmodified skeletal myoblasts and engineered cells in the presence of aTc were similar 
for all analyses, suggesting no adverse responses to retrovirally transduced cells. 
 
Discussion 
The exogenous regulation of Runx2-stimulated osteogenesis is significant for 
developing safe and controlled methods for gene therapy-based approaches to orthopedic 
regenerative medicine.  This system also represents a useful tool for studying the 
regulation of osteoblastic differentiation, including the modulation of kinetics and 
magnitude of gene expression and cellular activity.  We have demonstrated dose-
dependent control of osteoblastic gene expression and mineralization with aTc 
concentration as well as suppression of myogenic gene expression in primary skeletal 
myoblasts.  Following induction, osteoblastic markers were suppressible to background 
levels by addition of aTc to the media, demonstrating effective repression of Runx2-
mediated effects in the “off” condition.  The rate of mineralization could also be reduced 
by adding aTc to the media after 4 weeks of induction, demonstrating the potential to 
avoid bone overproduction in which bone production extends beyond the defect site.88,89  
Furthermore, cells precultured in differentiation conditions responded to the removal of 
aTc in the same fashion as cells in growth media, indicating comparable effects of Runx2 





Figure 6.6.  Regulation of in vivo mineralization with inducible Runx2 expression.  Cell-
seeded fibrous collagen scaffolds were cultured with or without 100 ng/ml aTc for 28 
days in vitro and implanted in the hind limb muscles of immunocompetent syngeneic 
mice for 28 days.  Mice received drinking water with or without 1 mg/ml aTc.  (A) 
Micro-CT showed significant mineralization of cell-scaffold implants in mice that did not 
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receive aTc (mean ± SEM, n=6, ANOVA p<5E-3, * vs. + aTc p<9E-3).  Mice receiving 
aTc produced background levels of attenuating material, similar to implants seeded with 
unmodified myoblasts (control).  (B) von Kossa staining showed significant phosphate 
deposits in the absence of aTc.  Scale bars indicate 100 µm.   (C) Hematoxylin and eosin 
staining showed greater cellularity and less residual scaffold material (S, pink) in the 
absence of aTc.  Scale bars indicate 100 µm (low magnification) and 10 µm (inset).  (D) 
Masson’s trichrome staining of collagen (blue) displayed large amounts of acellular 
residual scaffold in implants with aTc.  In addition to acellular scaffold material (S), 
implants without aTc contained significant collagen staining aligned and interwoven in 
highly cellularized regions, indicating matrix remodeling and/or deposition in a manner 
resembling intramembranous bone formation.  Endogenous muscle tissue (M) is stained 
red.  Scale bars indicate 50 µm.  Histological staining of implants seeded with 
unmodified skeletal myoblasts and engineered cells in the presence of aTc were similar 
for all analyses. 
 
 
by engineered myoblasts could be regulated with aTc on collagen scaffolds in vitro and in 
an ectopic implant site in vivo.  Greater cell numbers were consistently present on 
implants without aTc, despite equal cell numbers at implantation.  This result is 
potentially due to differences in proliferation of implanted cells, infiltration of native 
cells, and/or cell survival.  These differences are expected due to the varied autocrine and 
paracrine signaling of myoblastic (with aTc) and osteoblastic (without aTc) cell types, as 
well as differences in the structure of the local microenvironment of these samples, 
including extracellular matrix and mineralization.  Collectively, these results show 
efficient and precise control of Runx2 expression and its downstream effects.   
Inducible expression systems are notoriously troublesome in establishing 
successful routines for controlling transgene expression.74  Typical complications 
associated with these systems include low levels of induction in the “on” state, high 
levels of expression in the “off” state, insufficient sensitivity to inducer levels, promoter 
interference of vectors expressing multiple transgenes, gene silencing, and inadequate 
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methods for transferring multiple components of the system into target cells.  The results 
presented here demonstrate a system with undetectable transgene levels in the off state, 
high levels of expression in the on state for prolonged culture periods, and tight dose-
dependent control of transgene levels over two orders of magnitude of inducer 
concentration.  The success of this system may be attributed to the organization of the 
retroviral vectors, the antibiotic selection strategy for engineered cells, the cell type used, 
and/or the potency of Runx2 transcriptional activity. 
Although tetracycline and its derivatives are known to affect cell activity, the 
amounts of aTc used in this study are orders of magnitude below toxic concentrations.168  
Furthermore, primary skeletal myoblasts retrovirally engineered to constitutively express 
a Runx2 transgene154 showed equivalent levels of osteoblastic differentiation and in vitro 
and in vivo mineralization with or without aTc (unpublished results).  These results 
indicate that the effect of aTc on overall cell activity is specific to the regulation of 
Runx2 expression from the retroviral vector.  Interestingly, low levels of aTc (1 ng/ml) 
were necessary to suppress bone sialoprotein and Osterix expression, alkaline 
phosphatase activity, and mineralization.  However, 10 ng/ml aTc was necessary for 
complete suppression of osteocalcin expression, a direct target gene of Runx2.  This 
suggests that different threshold levels of Runx2 expression may be necessary to activate 
the many levels of the osteoblastic differentiation cascade.  In fact, Runx2 has been 
proposed as a scaffold for assembling transcriptional machinery in addition to its own 
transactivation capabilities.133  Furthermore, forced expression of Runx2 is commonly 
used to study mechanistic aspects of osteoblastic differentiation.  However, currently 
used techniques do not mimic the physiological expression patterns of this tightly 
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regulated transcription factor with respect to magnitude or duration.  Therefore this 
inducible expression system represents a promising tool for elucidating the effects of 
physiological and abnormal expression levels on the multifunctional roles of Runx2 in 
osteoblast differentiation. 
Significant levels of in vivo mineralization and collagen remodeling were detected 
by ectopically implanted cells in the absence of aTc.  These results establish inducible 
Runx2 expression in primary skeletal myoblasts as a promising strategy for cell-based 
orthopedic regeneration.   However, we did not observe the development of osteocytes, 
cartilage, or marrow cavities as has been demonstrated by ectopically implanted Runx2-
engineered cell lines in immunodeficient mice.78  This discrepancy may be due to the 
primary cells and immunocompetent mice used in the present study, and longer 
implantation times may be necessary for the development of more complex tissues.  
We utilized the “tet-off” system to regulate Runx2-stimulated osteogenesis 
because it is the most characterized and successful of the available inducible expression 
systems.  However, the clinical application of the “tet-off” system would require patients 
to receive tetracycline for an indefinite period of time following bone healing to suppress 
transgene expression and bone overproduction.  Therefore the “tet-on” system may be 
more clinically relevant for this application, considering the patient would only receive 
tetracycline during bone healing.  In fact, recent modifications of the “tet-on” system 
have shown improved induction levels and lower basal activity in the “off” state.93,94 
This system utilized two retroviral vectors to deliver the necessary components of 
an aTc-inducible Runx2 expression system.156  The tetracycline-inducible expression 
system has also been incorporated into a single autoregulatory retroviral cassette,169 
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which may circumvent clinical limitations associated with transducing cells with two 
independent retroviral supernatants.  Self-inactivating deletions within retroviral long 
terminal repeats can also be used to enhance expression from inducible promoters,65 
which may be limited in certain applications due to promoter interference.98  
Furthermore, tetracycline-regulated expression from adeno-associated virus (AAV) 
vectors71 may avoid safety concerns associated with insertional mutagenesis and 
retroviral integrations.170  In fact, allografts coated with AAV particles encoding 
osteogenic factors have recently been shown to increase bone healing.73  Despite the 
numerous advances in gene transfer and inducible expression systems74, it is clear that 
considerable research is necessary to optimize the effectiveness and clinical utility of 
these approaches.  Additionally, the optimal gene or combinations of genes to deliver is 
still unclear and may be application-specific.  In addition to BMPs and the Runx2 
transcription factor, promising results have been achieved with strategies focusing on 
VEGF and RANK-L,72 constitutively active BMP receptors,73 LIM-mineralization 
protein,81 and synergistic approaches incorporating multiple transgenes70,78 and 
transgenes supplemented with glucocorticoids83 or immunosuppressive agents.84,85  
Efficacy of these approaches may also be dependent on cell type24 and in vitro preculture 
of cell-scaffold composites.77  Nevertheless, inducible expression systems show 
significant promise in developing safe and controlled gene therapy strategies for bone 
tissue engineering.   
This work establishes a controlled and effective alternative to genetic engineering 
with secreted growth factors for gene therapy-based orthopedic regeneration.  
Additionally, this system represents a method for regulating the magnitude and temporal 
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expression of the osteoblastic phenotype.  Finally, this approach will be useful for 
elucidating biochemical properties of Runx2 activity and the stability of transgene-





This work has established Runx2-engineered primary skeletal myoblasts as a 
promising cell source for bone tissue engineering.  However, there are several areas of 
research to be pursued before this strategy is validated as a clinical approach for 
orthopedic regeneration.  Primarily, these cells should be implanted into an orthotopic 
defect and assessed for the ability to stimulate bone repair and restore function.  In 
particular, our collaborators have recently established rodent cranial67 and long bone 
segmental171 defect models.   Furthermore, the scaffold choice will be critical to 
interpreting the results of these experiments, as several recent studies have demonstrated 
substantial healing of bone defects with scaffolds alone67, or scaffolds supplemented 
directly with osteogenic proteins172 or gene delivery vehicles.64,72,73  Therefore it is 
critical to identify the defect criteria that justify the added complexity, cost, and safety 
concerns of implanting genetically engineered osteogenic cells to achieve bone healing. 
It is also important to identify the appropriate in vitro culture conditions to 
achieve optimal bone healing in vivo.  We have demonstrated that in vitro preculture of 
tissue engineered constructs can have a significant impact on in vivo mineralization.77,173  
However, it is unclear how in vitro maturation of the constructs affects the ability of 
native cells to infiltrate and remodel these engineered tissues, including the development 
of complex structures such as blood vessels and marrow cavities.  Additionally, 
incorporating methods to improve the mineral and cellular distribution throughout these 
constructs, such as perfusion culture139, may significantly enhance the activity of these 
genetically engineered cells.   
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Many gene delivery vehicles have been utilized for orthopedic gene delivery, 
including plasmid DNA64, adenovirus55,69, adeno-associated virus72,73, and retrovirus65,82.  
However, the optimal vehicle for orthopedic regeneration remains unclear.  We 
hypothesized that sustained retroviral expression of an osteogenic factor would be 
necessary to achieve significant levels of osteoblast differentiation and mineralization.  
However, recent work has suggested that short-term expression, similar to that of 
adenoviral and adeno-associated viral vectors, is sufficient for bone production.97  
Furthermore, retroviral vectors have been associated with adverse side effects due to 
insertional mutagenesis174, although these reports may be specific to the conditions of the 
particular study175.  Further work is necessary to elucidate the optimal gene delivery 
method, including examining the efficiency of bone healing, biocompatibility, and safety 
of various systems specifically in the environment of bone regeneration.   
We used the “tet-off” inducible expression system as a model for exogenously 
regulating osteoblastic differentiation and mineralization.  However, several other 
inducible expression systems have been developed or been improved during the course of 
this work95.  In particular, a system that activates expression in the presence of inducing 
agent would be more practical, as this approach would involve administration of the 
inducing agent only for the duration of bone healing.  In fact, the “tet-on” system has 
been recently modified for enhanced regulation of expression levels93,94 and is currently 
involved in clinical trials95.  Incorporating Runx2-based gene therapy into this system, or 
a similar strategy, would advance the clinical relevance of this approach. 
Present strategies in tissue engineering have focused on seeding a scaffold of 
uniform architecture with a single cell source to produce a homogeneous construct.  
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However, the native tissue to be repaired is typically heterogeneous with respect to cell 
type, composition, and function.  These tissues are often composed of transition zones 
which consist of gradients from one tissue type to another, such as bone-cartilage, bone-
ligament, bone-periosteum, and muscle-tendon interfaces. The successful integration and 
performance of engineered tissues is dependent on the development of new methods to 
replicate these transition zones in vitro.  Few attempts have been made to replicate the 
multi-functional nature of these tissues.  Typical approaches to this problem have 
involved seeding two independent scaffolds with different cell types and then fusing the 
two scaffolds together, or seeding opposite ends of a scaffold with different cell 
types176,177.  These methods do not accurately reproduce the transitional nature of these 
tissues and are therefore biologically and functionally inferior to the native tissue.  The 
successful engineering of these tissues will simulate their developmental nature: the 
influence of cell behavior by the chemotactic and haptotactic gradients of signaling 
molecules.  Current work by our group is using inducible regulation of Runx2-stimulated 
transdifferentiation of skeletal myoblasts into a mineralizing osteoblastic phenotype to 
simulate this developmental system in vitro.  We are applying a diffusion gradient of 
tetracycline across a hydrogel seeded with these genetically engineered cells to generate a 
continuous construct with muscle-like tissue at one end and bone-like tissue at the 
opposite end.  This work will establish a novel method for engineering complex and 
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